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ABSTRACT 
Age-related macular degeneration (AMD) is the major cause of vision loss in the industrialized 
countries in people above sixty years of age. The dry advanced form of the disease, also 
termed as geographic atrophy (GA), is characterized by the progressive death of retinal 
pigment epithelial cells (RPE) and consequent loss of the adjacent photoreceptor (PR) layer, 
leading to an impaired visual function. Since AMD has a multifactorial cause, including both 
genetic and epigenetic factors, a potential treatment for retinal regeneration relies on the 
generation of either autologous or allogeneic RPE and PR cells from human pluripotent stem 
cells (hPSC) in vitro. 
The overall aim of this thesis was to develop both in vitro and in vivo methods and models to 
move forward a stem-cell based replacement therapy for patients suffering from dry advanced 
forms of AMD.  
Specifically, we first developed a spontaneous, xeno-free and defined protocol to derive RPE 
from human embryonic stem cells (hESC-RPE) that acquired specific morphological and 
functional characteristics of native RPE. Additionally, we developed a large-eyed model (rabbit 
eye) with relevant pre-clinical imaging and surgical advantages when compared to other more 
commonly used rodent models. In fact, both the subretinal injections of PBS or the chemical 
NaIO3 created a retinal degeneration phenotype very similar to the lesion present in GA 
patients with RPE damage and PR loss. A next logical step was to evaluate the behavior of 
the hESC-RPE in such models of degeneration. From these studies, we first showed that 
hESC-RPE can rescue the neuroretina from further damage induced at the moment of 
subretinal injection, and second, that hESC-RPE are not able to integrate in areas of profound 
retinal degeneration caused by a 7-day pre-injection of either PBS or NaIO3, therefore 
supporting the idea of an early treatment. The use of allogeneic hESC as a transplantable 
source comes together with the forthcoming rejection of the donor cells. We then sought to 
create universal cells that lack HLA-I (hESC-RPEB2M-/- using CRISPR-Cas9 technology) able 
to evade the host adaptive immune system. Upon co-culture with T-cells under stimulatory 
conditions, the engineered hESC-RPEB2M-/- dampened CD8+ T-cell proliferation and when 
mixed with natural killer (NK) cells, a cytotoxic response was triggered. Furthermore, after 
transplantation of the hESC-RPEB2M-/- in the rabbit xenogeneic model, early stage rejection 
was reduced and the appearance of anti-human antibodies rejection associated with late 
rejection was delayed. 
Altogether, the studies described in this thesis show evidence that allogeneic replacement 
therapy using subretinal injection of hESC-RPE in suspension can be a successful treatment 
if (i) the derived cells retain native RPE cell properties; (ii) the cells are transplanted early 
enough so the subretinal milieu supports their integration; and (iii) the cells can be engineered 
so that they can evade the host immune system and consequent graft rejection.      
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1 INTRODUCTION  
1.1 THE RETINA 
The retina is part of the central nervous system and it is defined as the laminated neural 
component of the eye located in the inner side of the eye ball that contains the machinery to 
process the primary visual pathways (Purves et al., 2004). Its main function is analog to a film 
or a CCD in a camera: the visual field is captured by the optics of the eye that create a focused 
two-dimensional image on the retina, which will be translated into electrical impulses for the 
brain to create a visual perception.  
During vertebrate embryonic development, the retina forms as an outpocketing of the ventral 
diencephalon neuroepithelium (neurectoderm origin) to form the optic vesicle (regulated by 
PAX6, RX, OTX2, SIX3/6 and LHX2 transcription factors), which undergoes invagination to 
form a double-layered optic cup. The distal/inner wall of the optic cup gives rise to the 
multilayered neural retina (guided by FGF-induction of VSX2 and SOX2 transcription factors), 
while the proximal/outer wall develops into the single layer of RPE (promoted by TGFb 
signaling and molecules such as ActivinA). Finally, the presumptive neural retina of the optic 
vesicle invaginates to form the lens (of surface ectoderm origin and BMP-signaling dependent 
to activate PAX6 and SOX2 expression) (Fuhrmann, 2010; Heavner and Pevny, 2012).  
 
 
 
The adult vertebrate retina consists of ten different layers of cells including photoreceptors 
(PR), bipolar and ganglion cells interconnected by synapsis, in addition to an outer layer of 
pigmented epithelial cells (Figure 1). Specifically, from vitreous body to choroid they are: inner 
limiting membrane (Müller cells), nerve fiber layer (axons of ganglion cells), ganglion cell layer 
FIGURE 1. Schematic view of 
the structure of the eye, with 
magnification on the retinal 
layers and its correspondence 
with histology.  
NFL (nerve fiber layer), GCL 
(ganglion cell layer), IPL (inner 
plexiform layer), INL (inner 
nuclear layer), OPL (outer 
plexiform layer), ONL (outer 
nuclear layer), ELM (external 
limiting membrane), IS/OS (inner 
segments/outer segments), RPE 
(retinal pigment epithelium), and 
BM (Bruch's membrane). 
Note inside the drawing of the 
INL, the horizontal cells in blue 
and the amacrine cells in purple.  
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(their axons become part of the optic nerve), inner plexiform layer (synapse between bipolar 
cell axons and ganglion and amacrine cell dendrites), inner nuclear layer (nuclei and cell 
bodies of amacrine, bipolar and horizontal cells), outer plexiform layer (rod and cone 
projections), outer nuclear layer (rods and cones cell bodies), external limiting membrane, 
layer of rods and cones (PR cells) and retinal pigment epithelium (RPE) layer. In short, they 
can then be grouped into four main processing stages laterally connected by horizontal and 
amacrine cells: photoreception, transmission to bipolar cells, transmission to ganglion cells 
and transmission along the optic nerve (Purves et al., 2004). 
In an inverted retina, as the vertebrate one is, the light passes through layers of neurons and 
capillaries to reach the light sensing cells or PR. There are two types: rods, which mainly 
function in dim light and provide lower-resolution black-and-white vision (scotopic vision); and 
cones, responsible for the high-resolution color perception during bright daylight illumination 
(photopic vision). For illumination that falls in between these two levels (mesotopic vision), 
both rods and cones contribute to pattern information, but the specifics of how it works is still 
unclear. An important structure to mention is the macula, which is an oval-shaped pigmented 
area near the center of the retina specialized in central, high-acuity color vision. Within the 
macula there is the fovea centralis that contains a high density of cones that provides that 
high-resolution (Purves et al., 2004).  
Once light reaches the PR their photopigmented membrane gets hyperpolized, contrarily to 
that in the dark where it remains depolarized, via a cascade triggered by 11-cis retinal to trans-
retinal isomerization leading to cyclic guanosine monophosphate (cGMP) degradation and the 
closing of the cell sodium channels. Thus, the amount of neurotransmitter (glutamate) 
released in bright light is reduced and the correspondent synaptic response is transmitted to 
bipolar and retinal ganglion cells. These excited ganglion cells will be responsible to generate 
action potentials that, through the optic nerve, will reach various parts of the brain and 
eventually create a representation of the external light stimuli (Mannu, 2014).  
Although retinal cellular composition and thickness are conserved in mammals (0.24 mm thick 
in mouse and in humans), eyes vary in size, refractive properties, retinal vasculature and visual 
photopigment (Blanch et al., 2012; Remtulla and Hallett, 1985). Additionally, all mammalian 
rod PR contain rhodopsin but both size and densities varies by animal size and 
diurnal/nocturnal behaviors. The proportion of cones and their function is highly variable and 
can be classified in two (short: blue/UV and medium: green wavelength for mice, rats, rabbits 
pigs and most New World primates), or three (allowing trichromatic color vision in Old World 
Monkeys and great apes) classes. Murine rodents have cones distributed throughout the 
retina, with dorsal-ventral differences; in rabbits and pigs cons are concentrated in a visual 
streak, while in diurnal primates at a fovea (same as humans) (Applebury et al., 2000; 
Famiglietti and Sharpe, 1995; Gerke et al., 1995; Wikler and Rakic, 1990). Regarding the 
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blood supply for the rabbit inner retina, it is mostly derived from the choriocapillaris 
(merangiotic); but in human, primate, pig, and rodent the inner retina is derived from central 
and cilioretinal arteries (holangiotic), and only the outer retina is supplied by the 
choriocapillaries. In rabbits, RPE is irregular in size and organization compared to the human 
regular hexagonal configuration, rod and cones are longer and thinner, and myelinated nerve 
fibers in the retina form nasal and temporal crescents about the optic disc (Purves et al., 2004).    
1.2 THE RETINAL PIGMENT EPITHELIUM 
The RPE is located between the choriocapillaris and the PR layer as depicted in Figure 1. 
RPE cells form a monolayer located on an extracellular basal membrane (Bruch’s membrane, 
BM), and have a hexagonal pigmented morphology with abundant microvilli in their apical part. 
BM is mainly comprised of collagen type IV and laminins, primarily the isoforms LN-111, LN-
332, LN-511 and LN-521, which are synthesized by the RPE and in turn adhered to BM via 
specific integrin interactions (Aisenbrey et al., 2006). BM has crucial structural and transport 
roles as being the substratum of the RPE and a vessel wall (Curcio, 2013). RPE cells are 
strongly attached to each other by tight junctions which makes the monolayer impermeable to 
the transport of water, electrolytes and larger molecules under physiological normal conditions 
(Campbell and Humphries, 2012). RPE cells have a fundamental role in maintaining the 
homeostasis of the retinal tissue, and particularly of the PR, which they are in direct contact 
with by providing nutrients and oxygen, and also being responsible for phagocyting the rod 
and cone outer segments and renewing photopigments. The RPE pigment contains melanin 
that absorbs stray light within the eye and also takes part in the phototransduction process 
(Strauss, 2005). Additionally, RPE cells secrete cytokines and growth factors in a polarized 
fashion (e.g. VEGF is produced basally towards the choroid, while PEDF or TGF-β are 
secreted apically towards the PR layer) contributing to a variety of functions, among which the 
creation of an immunosuppressive microenvironment in the subretinal space (Zamiri et al., 
2006; Zhu et al., 2011). Therefore, dysfunction of the RPE involves PR degeneration and 
choriocapillaris atrophy leading to a visual function impairment. 
1.3 AGE-RELATED MACULAR DEGENERATION 
Age-related macular degeneration (AMD) is the principal cause of severe vision loss in 
people over 60 years of age, with an incidence of almost 500.000/year in the Western world, 
particularly in individuals with Caucasian ethnicity (Gehrs et al., 2006). Today, AMD is 
estimated to affect 170 million worldwide, a number predicted to increase to 196 million in 
2020, and up to 288 million in 2040 (Wong et al., 2014), implying substantial social and 
financial consequences. AMD is a multifactorial disease where both genetic and 
environmental causes are involved in its etiology. Factors associated with damage to the 
RPE, the BM, or the choriocapillaris include: oxidative stress, smoking, and mutations in the 
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complement system (e.g. Factor H, components C3 and C2), or in the lipoprotein cholesterol 
pathway. A more exhaustive study of AMD risk factors has been reviewed by Sobrin and 
Seddon (Sobrin and Seddon, 2014). 
 
In general terms, AMD can be classified according to the degenerative status of the retinal 
tissue. Early and intermediate forms of AMD are characterized by the thickening of BM and 
the appearance of sub-RPE deposits called drusen. The progressive accumulation of 
confluent drusen will lead to cumulative degenerative changes in RPE, BM, and 
choriocapillaris, culminating in advanced forms of the disease. These include neovascular 
AMD (also termed exudative or advanced "wet" AMD), which is characterized by the 
abnormal growth of choroidal vessels through the BM causing subretinal edema and 
hemorrhage (Ambati et al., 2003). Due to the abnormal angiogenesis of the vessels, this 
pathology is termed choroidal neovascularization (CNV). After the recognition of VEGF as a 
critical inducer of CNV, anti-VEGF treatment has become a gold standard making 
neovascular AMD a treatable condition if diagnosed in time. The second form of advanced 
AMD is geographic atrophy (GA) (also termed advanced "dry" AMD). As the name implies, 
GA is devoid of CNV and is characterized by well demarcated areas of RPE loss together 
with outer retinal atrophy (Ambati et al., 2003; Sunness, 1999). GA is responsible for 33% 
of visual loss in patients with AMD (80% among the advanced AMD cases) and is more 
prevalent among individuals older than 75 years old (Ferris et al., 1984).  
Noninvasive retinal imaging techniques comprise spectral domain-optical coherence 
tomography (SD-OCT), infrared-confocal scanning laser ophtalmsocopy (IR-cSLO) and 
blue-light fundus autofluorescence (BAF). SD-OCT relies on the interference between the 
reference optical path and the path reflected back from the eye (van Velthoven et al., 2007), 
IR-cSLO uses 820-mm fluorescence to create an en-face fundus reflectance image of the 
outer retina and RPE, and BAF a 488-nm laser excitation to capture the autofluorescence 
emitted by fluorophores in the RPE (Delori et al., 1995; Elsner et al., 1996). Together, these 
multimodal methods provide detailed frontal and sagittal segmentation of the neurosensory 
retina and RPE, and have played an essential role as diagnostic and prognostic tools (Gobel 
et al., 2011) (Figure 2). For instance, SD-OCT of eyes with GA shows thinning of the outer 
nuclear layer, loss of the RPE, and choroidal atrophy (Forte et al., 2012; van Velthoven et 
al., 2007) (Figure 2C); whereas in BAF, the fundus of the diseased GA eyes depicts a clearly 
distinguishable fluorescent pattern characterized by demarcated patches of 
hypoautofluorescence in areas of RPE loss and the presence of a surrounding 
hyperautofluorescent rim (Delori et al., 1995; Gobel et al., 2011; Holz et al., 1999; Holz et 
al., 2015) (Figure 2B). The understanding of the latter pattern is yet to be clarified. Finally, 
other techniques such as microperimetry can be used to assess macular function of AMD 
affected eyes (Wu et al., 2014). 
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Although neovascular AMD is currently treated with anti-VEGF therapies, nowadays there 
is no remedy available for GA. Today’s strategies to face a possible therapy involve: (i) 
preventing RPE dysfunction or death with neuroprotective agents; (ii) maintaining for an 
extended time the RPE function by providing the stressed cells support (e.g. with specific 
factors, or cellular or basal membrane components), and (iii) replacing the diseased or lost 
RPE with a healthy RPE layer created ex vivo. The answer for a future treatment most likely 
relies on the combination of several of these strategies. In this thesis, we studied tissue 
replacement as a feasible approach for treatment of GA. 
1.4 RPE REPLACEMENT AS TREATMENT FOR GA 
As discussed above, RPE cells contribute with vital functions to the correct performance of 
the subretinal microenvironment, that is the reason why it is considered to be a key target 
for therapeutic interventions for both types of advanced AMD. However, since RPE cells do 
not have the ability to self-renew, some replacement attempts have been pursued either 
using autologous RPE harvested from the retinal periphery or using allogeneic fetal or adult 
RPE from cadaveric donors (Algvere et al., 1994; Phillips et al., 2003). Such transplants led 
to improved vision in some cases (Radtke et al., 2008) but have the disadvantage of coming 
from a limited source and, if autologous, they may carry predisposing genetic defects. In that 
sense, a more abundant and robust source is needed to provide a viable supply of healthy 
cells. 
Such source could be provided from stem cells. Stem cells are a cell type that by definition 
has two properties: (i) the ability to self-renew, proliferate and give rise to the same cells 
maintaining their potency; and (ii) the capacity to differentiate into more specialized cell 
types. Depending on how restricted they are in their differential potential, they can be 
classified as totipotent, pluripotent, multipotent, oligopotent, or unipotent. Mainly two types 
FIGURE 2. Multimodal imaging illustrating an eye with 
geographic atrophy.  
(A) Multicolor and (B) BAF image of a patient with advanced 
dry AMD showing the demarcated boundaries of GA. Note in 
B the hypo-BAF atrophic area surrounded by a hyper-BAF 
rim compared to the non-atrophic zones. (C) SD-OCT image 
depicting loss of RPE layer (between red arrows) and 
thinning of the outer retinal layers that also appear atrophic. 
Adapted from Nazari et al., 2015. 
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of pluripotent stem cells have been used for differentiation into RPE cells, human embryonic 
stem cells (hESC) and induced pluripotent stem cells (iPSC). However, multipotent cell types 
(or adult stem cells) such as fetal umbilical cord blood cells, hematopoietic, or mesenchymal 
stem cells are also being explored as therapies for retinal diseases (Fox et al., 2014; Mooney 
and Lamotte, 2010), yet up to date hESC or iPSC are arising as a more promising RPE 
source. 
1.4.1 Differentiation of hESC into RPE 
ESC are derived from the inner cell mass of a blastocyst embryo. These cells are considered 
pluripotent since they can differentiate into any cell type of the three germ-layers: ectoderm, 
endoderm and mesoderm (Thomson et al., 1998). Several protocols have used ES cell lines 
from several animals (e.g. monkey, mouse) to generate RPE cells (Haruta et al., 2004; 
Kawasaki et al., 2002; Osakada et al., 2009a). However, a xenotransplant of cells will often 
cause severe immunorejection. Thus, after the derivation of human stem cell lines from 
supernumerary human embryos, plentiful differentiation protocols to differentiate hESC into 
RPE cells emerged. They can be classified as spontaneous or directionally induced, both 
with possibilities to be xeno-free and/or defined. 
Regarding spontaneous differentiation of hESC into RPE, which includes removal of basic 
fibroblast growth factor (bFGF) (an important factor for keeping the undifferentiated state of 
hESC), multiple studies have shown that RPE cells can be derived on several substrates 
ranging from inactivated mouse embryonic fibroblasts (MEFs)-, Matrigel-, poly-D-lysine-, or 
laminin-coated dishes, in addition to the use of different types of hESC culture media (e.g. 
DMEM/F12, KSR, mTeSR1, XVIVO 10) (Klimanskaya et al., 2004; Lane et al., 2014; Lund 
et al., 2006; Maruotti et al., 2013; Pennington et al., 2015; Plaza Reyes et al., 2016; Rowland 
et al., 2013; Vaajasaari et al., 2011). However, spontaneous protocols have the shortcoming 
of having long differentiation processes and potential less pure cultures. 
hESC can also be directionally induced into hESC-RPE using several approaches 
comprising a two-stage induction via neural precursors (Cho et al., 2012; Choudhary et al., 
2017; Zhu et al., 2013), the use of Nicotinamide and/or Activin A (Idelson et al., 2009; Leach 
and Clegg, 2015; Maruotti et al., 2015; Osakada et al., 2009b), or the combined used of 
retinal inducing factors (IGF1, Noggin, Dkk1, and bFGF together with Nicotinamide, Activin 
A, SU5402, and VIP) at the appropriate times to produce a faster differentiation (Buchholz 
et al., 2013). 
Additionally, a remarkable number of protocols has emerged under the concept of trying to 
create clinically compliant cells, meaning an animal-free and defined product to avoid any 
possible microbial contamination or risk of rejection potentially brought by non-human 
protein into the cells during their time in culture. These xeno-free and/or defined protocols 
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rely on the spontaneous derivation of hESC-RPE either on recombinant matrices or using 
chemically defined factors/media, or both (Hongisto et al., 2017; Maruotti et al., 2013; 
Pennington et al., 2015; Plaza Reyes et al., 2016; Vaajasaari et al., 2011). 
In all protocols, enrichment of hESC-RPE still needs to be performed either through 
mechanic or enzymatic procedures to remove the growing undifferentiated parts. Briefly, a 
standard characterization of the differentiated hESC-RPE would consist of the following 
steps: (i) verify the pigmented hexagonal morphology of the derived RPE cells and the apical 
microvilli and melanin pigments, which could be seen by conventional and electronic 
microscopy, respectively; (ii) analyze the presence of RPE-specific genes such as RPE65, 
BEST1, CRALBP, or MITF expressed as transcripts or proteins; (iii) analyze the purity of the 
culture by searching for genes of contaminating cell types (e.g. pluripotent stem cells, neural 
cells, fibroblasts, endothelial or non-RPE melanocyte markers) by qPCR, immunostaining 
or RNA single cell sequencing, in addition to tumorigenicity and biodistribution animal 
studies; (iv) confirm the functionality of the cells by analyzing their phagocytic capacity with 
FITC-labeled PR outer segments (POS) or verifying the presence of polarized channels (e.g. 
Na+/K+ expressed apically or BEST1 basally) via immunostaining; and (v) demonstrate the 
polarized secretion of growth factors such as VEGF or PEDF, and validate the presence of 
tight junctions through transepithelial resistance (TEER) measurements.  
1.4.2 Differentiation of iPSC into RPE 
The iPSC technology that emerged in 2006 has been a breakthrough capable of overcoming 
the possible ethical concerns and the possible rejection issues that allogeneic transplants 
with hESC-derived cells could entail. In an independent manner, Yamanaka and Thomson 
demonstrated that a terminally differentiated cell type (e.g. mouse fibroblasts) could be 
reprogrammed to an earlier state in its potency by the simple introduction of four crucial 
transcription factors: Oct3/4, Sox2, c-Myc, and Klf4; or Oct3/4, Sox2, Nanog, and Lin28, 
respectively (Takahashi and Yamanaka, 2006; Yu et al., 2007). The cells exhibited the 
morphology and properties of a pluripotent cell in vitro and in vivo. Such cells have been a 
promising source of patient-specific cells, easy to derive from an accessible source that 
would in theory eliminate the risk of immune rejection, thus inspiring researchers to develop 
iPSC-RPE as an autologous AMD treatment. Although iPSC-RPE have been derived and 
characterized showing a full range of the RPE features stated above (Buchholz et al., 2009; 
Carr et al., 2009; Hu et al., 2010; Kamao et al., 2014; Kokkinaki et al., 2011; Maruotti et al., 
2013), a previous study showed that hESC-RPE seem to resemble human fetal RPE more 
closely than iPSC-RPE (Liao et al., 2010).  
Despite the ideal therapeutic potential of the iPSC, still some concerns remain to be further 
explored for its optimal clinical use, such as reprogramming efficiency and safety of the cells 
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after the reprogramming procedure; as well as economical, time, and labor costs of the 
technology. Moreover, it is worth noting that iPSC derived from an AMD patient would still 
carry the genetic aberrancies and changes that predisposed that patient for the disease. In 
any case, amongst the potential clinical use, iPSC are an excellent source of cells for drug 
testing, investigating developmental biology, and disease modeling, as it has been shown 
for instance in a cell model of retinitis pigmentosa (RP) derived from RP patients that 
elucidated some of the possible pathogenic mechanisms of the disease (Jin et al., 2011).  
1.5 ANIMAL MODELS FOR AMD 
The ideal animal model to study AMD should be inexpensive, recapitulate the histological and 
functional changes but evolve in a rapid time course to allow more efficient studies. However, 
as mentioned earlier, AMD is a multifactorial and complex disease involving both genetic (i.e. 
multiple genetic polymorphisms that altogether contribute to the increased risk for AMD) and 
epigenetic factors. This in addition to the anatomical differences between species and the 
human retina hinders an accurate model of disease. Nonetheless, models of AMD have been 
generated in mice, rats, rabbits, pigs, and non-human primates and have contributed to 
unravel many important aspects about the underlying pathology of the disease (Fletcher et al., 
2014; Pennesi et al., 2012; Zeiss, 2010). Despite the fact that rodents lack an anatomical 
macula and its PR are mainly composed of rods, they are low cost animals, they allow genetic 
manipulation, and the disease progression can be studied on a relatively quick time scale; 
advantages that are not offered by non-human primates although they possess the closest 
retinal anatomy to humans. Large-eyed models (e.g. rabbits, pigs, non-human primates) are 
more valuable regarding eye size and clinical relevance of the surgical procedures, which are 
in various ways useful for assessing the potential efficacy of a cell replacement treatment. 
A very well-established preclinical animal model that mimics dry AMD/PR degeneration is the 
Royal College of Surgeons (RCS) rat. Specifically, they have a mutation in the MERTK gene 
which disrupts the RPE phagocytosis activity thus leading to outer retinal degeneration 
(D'Cruz et al., 2000). In addition, several other animal models have been developed following 
reported human mutations associated with hallmarks of early stages of the disease. These 
include animals with the following alterations: developing of drusen or drusen-like deposits 
(e.g. Crb1rd8 mutants), thickening of the BM involving lipid accumulation and defective lipid 
transport (e.g. mice under high-fat, high-glycemic-index diet, mice with alterations in 
cholesterol related genes such as APOE, LIPC, CETP and ABCA1 or in the lipid transport 
process: CD36-null mice) and extracellular matrix proteoglycans (e.g. mice overexpressing 
Htra1), immune dysregulation (e.g. affecting the complement system: Cfh-null mice and other 
variants, or monocyte migration to the subretinal space: Ccl2-null, Cx3cr1-null mice), oxidative 
stress (e.g. smoking, light exposure, and mutations in mitochondrial genes affecting the 
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enzyme superoxide dismutase/SOD) (for detailed references see Fletcher et al review 
(Fletcher et al., 2014)). Early to intermediate signs of macular degeneration also occur 
spontaneously in Cynomolgus Monkeys (Macaca fascicularis with early onset) and Rhesus 
Monkeys (Macaca mulatta with age-related onset but not progressive), although advanced 
features are rarely part of the natural history of the macular degenerative disease in these 
animals (Zeiss, 2010). 
Modelling geographic atrophy in rodents becomes more difficult since it requires progressive 
deterioration of the retinal layers implying time and still multiple factors. However, alterations 
in chemokine pathways (e.g. Cx3cr1/Ccl2-/- mice if exposed to moderate level of light on a 
daily basis (Luhmann et al., 2012; Vessey et al., 2012)), defects in mitochondrial enzymes 
(e.g. Sod1-null and Sod2 knockdown mice (Imamura et al., 2006; Justilien et al., 2007)) or in 
the NLRP3 inflammasome (e.g. DICER1 knockout mice (Kaneko et al., 2011; Tarallo et al., 
2012)) have been reported to induce PR and RPE cell dysfunction and loss. For mimicking 
CNV, laser or subretinal injury is the most commonly used method, but also subretinal VEGF 
gene transfer and genetic mice models of angiogenesis.   
Other methods to induce retinal degeneration that in turn allow the recapitulation of more 
advanced stages of the AMD disease include: systemic or subretinal injections of sodium 
iodate and mechanical debridement of the RPE layer (Bartuma et al., 2015; Bhutto et al., 2018; 
Carido et al., 2014; Chowers et al., 2017; Hayashi et al., 1999; Kiilgaard et al., 2007; Leonard 
et al., 1997; Machalinska et al., 2010; Nork et al., 2012; Valentino et al., 1995; Yang et al., 
2014). In fact, these are the most common techniques used to model retinal degeneration in 
large-eyed animals considering their difficulties for genetic manipulation.  
1.6 SUBRETINAL HESC-RPE TRANSPLANTATION 
Once an appropriately characterized hESC-RPE line has been established, a program for 
clinical transplantation may be considered. However, several important points need to first be 
addressed, including the manner in which the cells will be placed into the subretinal space, 
the possible rejection of the implant, and the safety of the cells in the host or patient.  
1.6.1 Suspension Injections versus Monolayer-Sheet Engraftments 
Regarding the transplantation format, two different strategies have been proposed: (i) 
introducing a cell suspension of non-polarized stem cell-derived RPE into the subretinal space; 
or (ii) implanting polarized sheets of stem cell-derived RPE cells with or without a supporting 
biomatrix. 
Cell suspensions may integrate into the host subretinal space providing some beneficial 
effects, such as secreting growth factors and trophic molecules. The transplantation technique 
in large-eyed animals and humans undergoes a pars plana vitreactomy and generation of a 
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detachment or bleb where the cells will be then placed (Klimanskaya et al., 2004; Lund et al., 
2001a; Lund et al., 2001b; Schwartz et al., 2012). In small-eyed rodents, the subretinal space 
is instead reached through the sclera (implying the rupture of the blood retinal barrier) without 
the need of performing a vitrectomy or retinotomy (Carido et al., 2014; da Cruz et al., 2007; 
Idelson et al., 2009; Lund et al., 2006; Vugler et al., 2008). 
A concern raised with suspension transplants is the possible formation of multilayered clumps 
of cells that would damage the retina (Kamao et al., 2014). Another aspect to take into account 
is the status of the BM that in a diseased eye may not support RPE adhesion (Curcio, 2013; 
Sugino et al., 2011). To increase the likelihood of success, suspensions may need to be 
transplanted with a more supportive carrier (e.g. hydrogel), in an earlier disease state where 
the BM will be conserved enough, or the RPE cells may be manipulated to overexpress 
molecules such as integrins that would improve their attachment to the BM (Heller and Martin, 
2014).  
Transplantation of polarized hESC-RPE monolayer sheets seeded on a biomatrix is intended 
to mimic the native RPE and BM thereby potentially facilitating functional integration. A 
challenge with such membranes is to safely deliver them into the subretinal space. Several 
types of substrates have been used including plasma polymers, Parylene C, polyimide, and 
polyester membranes (Diniz et al., 2013; Kearns et al., 2012; Stanzel et al., 2014; Subrizi et 
al., 2012). It is crucial that these materials are inert to avoid rejections and allow diffusion of 
small and mid-range sized molecules. Moreover, they need to be flexible to facilitate delivery 
yet strong enough to preserve the cells as a monolayer. The surgery consists of conventional 
pars plana vitreactomy with subretinal implantation through a retinotomy that is considerably 
larger than for suspensions, thus increasing the risk of retinal detachment and possibly 
immune infiltration and graft rejection. There is also concern that these complex constructs 
may not be biocompatible causing retinal atrophy at the transplantation site (Ilmarinen et al., 
2015; Stanzel et al., 2014). However, if successful, it has been shown that cell survival is 
improved when cells are transplanted as monolayer grown on sheets when compared to cell 
suspension injections (Diniz et al., 2013). Some of these suspension and scaffolds 
approaches are currently being tested in clinical safety trials (see section 1.7). 
Current methods to evaluate the structural and functional integration of hESC-RPE include 
the use of real-time imaging techniques mentioned above (e.g. SD-OCT, BAF, IR-cSLO). In 
addition, histology and immunohistochemistry may give information on the fate of the 
transplanted cells as well as the surrounding retinal layers. Functionality may be tested by 
immunostaining for rhodopsin to demonstrate engulfment of POS, electroretinography (ERG) 
to determine the electrophysiologic response of the retina or by the use of behavioral tests to 
assess visual function (e.g. measures of visually-guided behaviors, optokinetic head-tracking 
(OHT) (Cowey and Franzini, 1979), and superior colliculus recording). 
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1.6.2 Immunologic Challenges of Stem Cell-Derived RPE Transplants 
Upon transplantation, it is important to consider the immune properties of the stem cell-derived 
tissue and the environment they are intended to regenerate. Although it is well established 
that the eye is an immune-privileged site (Wenkel and Streilein, 2000), thus providing some 
protection against an immune response to the transplant, this barrier may be compromised 
under disease or surgical conditions. This is critical since any degree of immune response 
may lead to rejection of the transplanted cells. Indeed, even with a robust anti-inflammatory 
regimen, studies have shown progressive loss of donor cells in the subretinal space in animal 
models (Stanzel et al., 2014; Streilein et al., 2002). 
Among the molecular mechanisms that have been suggested to be involved in subretinal 
immune privilege, the intrinsic properties of the RPE cells are fundamental. These include: (i) 
secretion of cytokines (e.g. TGF-β, PEDF, thrombospondin, somatostatin) with the ability to 
suppress both adaptive and innate immune systems (Sugita et al., 2006; Sugita et al., 2010; 
Sugita et al., 2009b; Zamiri et al., 2005; Zamiri et al., 2006); (ii) induction of macrophages to 
produce IL-10, which is known to down-regulate surface expression of the major 
histocompatibility complex MHC-II that in turn is the primary trigger for T-cell mediated immune 
responses (Zamiri et al., 2005; Zamiri et al., 2006); and (iii) secretion of TGF-β2 promoting the 
eye-specific regulatory T-cell (Tregs) differentiation (Hirsch et al., 2015). Tregs have an 
important role in suppressing effector T-cells, an action that protects tissues from aberrant 
immune reactivation, and have been proven to prevent immune rejection in graft-versus-host 
disease models (Cai et al., 2017; Hippen et al., 2011; Sakaguchi et al., 2008). On human RPE 
cells, Tregs are known to inhibit interferon-gamma IFN-g-induced expression of MHC-II thus 
mitigating T-cell proliferation (Sugita et al., 2008; Sugita et al., 2009a). 
In brief, the two main immune mechanisms triggered when the host retina receives non-
autologous tissue or cells are: the innate system (cellular and humoral including complement), 
activated either by contaminating microbial products and endogenous proinflammatory factors 
released during the transplantation procedure; or stress-induced ligands that would activate 
natural killer (NK) cells (Figure 3A). Additionally, the adaptive response is also activated mainly 
triggering effector T-cells that will respond to either mismatched donor MHC antigens 
presented via MHC-I, or other non-self antigens presented via MHC-II of the host antigen 
presenting cells (APCs) (mechanisms known as direct or indirect allorecognition, respectively, 
Figures 3B and 3C) (Lechler et al., 2005; Murphy et al., 2011). This results in the expansion 
of allospecific cytotoxic (CD8+) and helper (CD4+) T-cells and the generation of alloantibodies 
through B-cell activation leading to graft rejection (Bradley et al., 2002). In fact, Zhang and 
Bok demonstrated that the expression of MHC-II on the grafted RPE cells under specific 
conditions promotes a progressive functional decline of the transplanted cells (Zhang and Bok, 
1998), thus reinforcing the crucial role of MHC-II in long-term survival of the transplants. 
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Consequently, it is essential to apply strategies that eliminate or minimize the risk of rejection 
of allogeneic stem cell-derived grafts. In addition to conventional immunosuppressive 
regimens in which possible toxic effects limit their efficiency (Tang and Drukker, 2011), some 
other approaches have been suggested: (i) mesenchymal stem cells given their 
immunosuppressive properties (Joe and Gregory-Evans, 2010); (ii) ES cells banking with 
known major histocompatibility complex antigens for matching recipients with the closest 
donor MHC antigen composition (Nakajima et al., 2007; Taylor et al., 2005; Thomson et al., 
1998); (iii) peri-operative immunosuppression in the host after transplantation to provide the 
maximum protection for the limited number of cells introduced (Del Priore et al., 2003); (iv) if 
aiming for subretinal transplantation of RPE sheets, use of inert and biocompatible materials 
such as parylene or dissolvable gelatin; (v) inducing tolerance with a specific 
immunosuppressive drugs and dosing, or educating the recipient immune cells using donor-
recipient hematopoietic chimeras or/and ex vivo adoptive cell therapy with donor-antigen-
specific Tregs (Pasquet et al., 2011; Tang and Bluestone, 2013); and (vi) eliminating or 
reducing MHC (I and/or II) expression on donor cells limiting their recognition by the immune 
system by knock-ins with small interference RNA (siRNA) or short hairpin RNA (shRNA) 
(Burnett et al., 2011), or knock outs using viral or genetic engineering targeting (Abrahimi et 
al., 2015; Chen et al., 2015; Lu et al., 2013; Riolobos et al., 2013; Torikai et al., 2013). 
 
FIGURE 3. Schematic view of the immune mechanisms of 
rejection.  
(A) Innate immune system (NK-cells) recognition of the 
donor/target cell via miss-matched or “missing self” MHC class 
I molecule which will trigger a NK cytotoxic response towards 
the graft. (B) Direct allorecognition mediated by recipient T-
cells after the detection of a miss-matched donor MHC 
molecule. Note that the expression of molecules such as Fas 
Ligand can confer donor immune-advantage. (C) Indirect 
allorecognition mediated by recipient APC cells (e.g. DC) 
presenting donor antigens to recipient T-cells which will lead to 
graft cytotoxicity and alloantibody production. Adapted from 
StemBook (Drukker, 2008).  Chronic rejection 
Acute rejection Acute rejection 
Donor cell 
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1.6.3 Safety Evaluation of Transplanted hPSC-RPE Cells 
To ensure a safe translation of derived RPE cells as a feasible option for patients, a 
standardized strategy that eliminates potential hazards associated with this type of treatment 
should be adopted. Prior to transplantation, stem cell-derived RPE cells should on the one 
hand prove to be pure or free of undifferentiated cells and pathogens and, on the other, they 
should show the ability to act as true RPE cells, both genetically and functionally as it has 
been described in previous sections.  
Tumorigenicity studies are important to verify the inexistence of remnant pluripotent cells, thus 
demonstrating the inability of the transplanted cells to create teratomas (a tumor composed of 
tissues of ectodermal, mesodermal and endodermal origin) in an immunodeficient 
environment (e.g. CD-1 Nude Mouse, NU/NU Mouse, and BALB/c Nude Mouse) (Bouma et 
al., 2017; Kanemura et al., 2014). On the same line, DNA sequencing of the derived cells is 
another informative approach to further explore acquired mutations that could lead to disease 
or tumor formation (Bhutani et al., 2016). Preclinical animal toxicology, safety and efficacy 
studies are relevant to determine the potential expression of known proto-oncogenes or 
tumorgenesis risk. Additionally, biodistribution studies assessing the lack of migration of the 
cells from the transplantation site to other animal body organs are also critical. One should 
also be aware of the potential epigenetic modifications in the differentiated cells (especially 
after iPSC reprogramming), which may increase the risk of dedifferentiation drift of the derived 
RPE cells (Huo et al., 2014). The surgical procedure should also be carefully assessed to 
faithfully simulate the method to be used in humans, thus minimizing any possible further 
complications in this aspect.  
To help such evaluations, some international guidelines to assess malignant potential of hPSC 
and derived products have been recently reported (Andrews et al., 2017; International Stem 
Cell, 2018). Finally, Good Manufacturing Practices (GMP) assuring sterility and traceability 
should be enforced throughout the clinical trial process (Bharti et al., 2014). 
1.7 STEM CELL-DERIVED RPE CLINICAL TRIALS FOR AMD 
Currently, there are at least 14 clinical trials ongoing testing stem cell-based replacement 
therapies registered in the International Clinical Trials Registry Platform (ICTRP) of the World 
Health Organization, aiming to treat advanced forms of AMD (Chichagova et al., 2018). All of 
these are to date in early phases, mainly assessing the safety and survival of the transplanted 
cells rather than efficacy. Studies include hESC-RPE, iPSC-RPE, hUTSC (human umbilical 
tissue-derived stem cells), BMHSC (bone marrow hematopoietic stem cells), HuCNS-SC 
(human central nervous system stem cells), Human-Fetal derived cells and Adipose-Derived 
stromal cells, with the majority of studies focusing on hESC-RPE or iPSC-RPE. Different cell 
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delivery methods are being tested in parallel, including subretinal suspensions or sheets as 
well as intravitreal injections.  
The major hESC-RPE and iPSC-RPE trials include: - Astellas Institute for Regenerative Medicine (Marlborough, Massachusetts, United 
States of America, NCT01344993) trial using subretinal hESC-RPE suspensions. 
They completed Phase I trial for dry AMD and Stargardt disease (18 patients). The 
authors reported evidence of long-term safety (5 years), graft survival, and possible 
biological activity of the transplanted hESC-RPE cells in AMD patients (Schwartz et 
al., 2012; Schwartz et al., 2015; Schwartz et al., 2016; Song et al., 2015). - California Project to Cure Blidness/Regenerative Patch Technologies, Ltd. (California, 
United States of America, NCT02590692) trial supported by the California Institute for 
Regenerative Medicine (CIRM) using subretinal hESC-RPE monolayers on an 
ultrathin parylene scaffold. They recently completed In Phase I/II clinical trials for dry 
AMD trials (20 patients) and reported safety and suggested efficacy (in the short term) 
in some patients with severe vision loss (Kashani et al., 2018).  - Cell Cure Neuroscience Ltd. (Hadassah Ein Kerem University Hospital, Israel, 
NCT02286089) trial using subretinal hESC-RPE suspensions for dry AMD. Currently 
in PhaseI/II trial (15 patients).  - London Project to Cure Blindness (LPCB)/University College London (London, United 
Kingdom, NCT01691261) trial using hESC-RPE monolayers on a polyester scaffold. 
They recently completed Phase I clinical trial for acute wet AMD (10 patients) and 
reported feasibility and safety of the hESC-RPE patch transplantation (da Cruz et al., 
2018).   - RIKEN Center for Developmental Biology (Kobe, Japan, NCT01691261) trial using 
iPSC-RPE monolayers on a collagen gel initially used as a temporary scaffold. This 
trial stands as the first clinical study using autologous iPSC-derived cells with 6 patients 
with wet AMD. However, the first treated patient in 2014 was reported with safety 
issues after transplantation and the study has then been interrupted. They have 
nevertheless recently reported feasibility of sheet transplantation one year post-
surgery (Mandai et al., 2017). 
Other studies in Phase I clinical trial aiming for advanced dry AMD worth mentioning are: 
StemCells, Inc. (Newark, California, United States of America) trial and Janssen Research & 
Development, LLC (Titusville, New Jersey, United States of America) that use suspensions of 
HuCNS-SC and umbilical cord blood mesenchymal stem cells, respectively. Both studies are 
aiming to assess the safety and preliminary efficacy of the subretinal injections. 
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2 AIMS OF THE STUDY 
The general aim of this thesis was to develop both in vitro and in vivo methods and models to 
move forward a stem-cell based replacement therapy for patients suffering from the dry 
advanced form of AMD. 
The specific aims of the four projects were: 
I. To develop a xeno-free and defined protocol to derive RPE cells from hESC 
II. To develop preclinical large-eyed animal models that faithfully recapitulate the GA 
phenotype seen in human patients 
III. To assess the behaviour of the derived hESC-RPE upon transplantation in such 
models of degeneration 
IV. To generate HLA-I knock out hESC-RPE and evaluate their immunological 
properties in vitro and in the large-eyed rabbit model  
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3 MATERIAL AND METHODS 
3.1 ETHICS 
3.1.1 Human Embryonic Stem Cells 
Human embryonic stem cell (hESC) line HS980 was derived from supernumerary in vitro 
fertilized human embryos with a written consent from the donor and with the approval from the 
Regional Ethics Board (Dnr 2011/745-31/3). hESC were cultured under xeno-free and defined 
conditions according to the previously described method (Rodin et al., 2014a; Rodin et al., 
2014b). 
3.1.2 Animals 
New Zealand white albino rabbits (provided by Lidköpings rabbit farm, Lidköping, Sweden) 
aged 5 months and weighing 2.5 to 4.0 kg were used at St Erik Eye Hospital (Stockholm, 
Sweden) after approval by the Northern Stockholm Animal Experimental Ethics Committee 
(Dnr N25/14). All experiments were conducted in accordance with the Statement for the Use 
of Animals in Ophthalmic and Vision Research.  
3.2 CELL CULTURE 
3.2.1 Human ESC Maintenance 
hESC were maintained on hrLN-521 10 μg/mL in NutriStem hESC XF medium at 5% CO2/5% 
O2, and passaged enzymatically at a 1:10 ratio every 5-6 days. 
For passaging, confluent cultures were washed with DPBS and incubated for 5 min at 37°C, 
5% CO2/5% O2 with TrypLE Select. The enzyme was carefully removed and the cells were 
collected in fresh pre-warmed NutriStem hESC XF medium by gentle pipetting to obtain a 
single cell suspension. The cells were centrifuged at 300g for 4 min, the pellet was 
resuspended in fresh prewarmed NutriStem hESC XF medium and cells plated on a freshly 
hrLN-521 10 μg/mL coated dish. Two days after passage the medium was replaced with fresh 
prewarmed NutriStem hESC XF medium and changed daily. 
 
3.2.2 Human ESC Differentiation 
3.2.2.1 Suspension Embryoid Bodies 
Pluripotent stem cells were cultured to confluence on hrLN-521 and manually scraped to 
produce embryoid bodies (EBs) using a 1000 μL pipette tip. The EBs were cultured in 
suspension in low attachment plates at a density of 5-7x104 cells/cm2. Differentiation was 
performed in custom-made NutriStem hESC XF medium without bFGF and TGFβ and media 
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was changed twice a week. 10 μM Rho-kinase inhibitor was added to the suspension cultures 
only during the first 24 hours.  
Following five weeks of differentiation, pigmented areas were mechanically cut out of the EBs 
using a scalpel. Cells were then dissociated using TrypLE Select, flushed through a 20G 
needle and syringe. Cells were seeded through a cell strainer (ø 40 μm) on 20 μg/mL LN-
coated dishes at a cell density of 0.6-1.2x104 cells/cm2 and fed three times a week with the 
same differentiation medium referred above.  
3.2.2.2 2D Monolayer 
Pluripotent stem cells were plated at a cell density of 2.4x104 cells/cm2 on 20 μg/mL hrLN-111 
coated dishes using NutriStem hESC XF medium. Rho-kinase inhibitor at a concentration of 
10 μM was added during the first 24 hours, while cells were kept at 37°C, 5% CO2/5% O2. 
After 24 hours, hESC medium was replaced with differentiation medium NutriStem hESC XF 
without bFGF and TGFβ and cells were placed at 37°C, 5% CO2. From day 6 after plating, 
100 ng/mL of Activin A was added to the media. Cells were fed three times a week and kept 
for 4-5 weeks.  
Monolayers were then trypsinized using TrypLE Select for 10 min at 37°C, 5% CO2. The 
enzyme was carefully removed and the cells were collected in fresh pre-warmed differentiation 
medium by gentle pipetting to obtain a single cell suspension. The cells were centrifuged at 
300g for 4 min, the pellet was resuspended, passed through a cell strainer (ø 40 μm), and 
cells were seeded on LN-coated dishes (hrLN-521 20 μg/mL) at a cell density of 7x104 
cells/cm2. Re-plated cells were fed three times a week during the subsequent four weeks with 
differentiation medium. 
3.3 IMMUNE CELL CO-CULTURES 
3.3.1 With PBMCs/T-Cells (T-Cell Proliferation Assay) 
Day 30 (after replating) unstimulated or 2 days IFN-g pre-stimulated (100 ng/mL) hESC-RPE 
cells were trypsinized as described above, irradiated (30 Gy) and plated at a cell density range 
of 1x103 (1:500) - 5.5x105 (1:1) cells/cm2 (depending on the respective experiment) on hrLN-
521 coated dishes (20 µg/mL) using complete RPMI medium with 10% FCS. hESC-RPE cells 
were left for at least 3 hours to attach to the plate. Secondly, PBMCs were isolated from buffy 
coats of healthy donors by a Lymphoprep density gradient. After washing with DPBS, cell 
numbers were assessed by counting with Türks solution, and they were then either stained 
with CellTrace CFSE Cell Proliferation Kit (2.5 µg/mL) or divided into two tubes for CD4+ and 
CD8+ isolation with commercially available CD4 and CD8-islation beads in accordance with 
the instructions of the manufacturers. Finally, 1 million of the labelled or unlabelled PBMCs, or 
isolated CD4+ or CD8+ cells were plated per well in a 24-well plate on top of the attached 
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unstimulated or pre-stimulated hESC-RPE; and IL-2 (1 ng or 100U), CD28 (1.25 µg/mL) or 
OKT-3 (25 ng/mL) molecules were added to each well if required. Co-cultures were 
maintained for 5 days at 37°C for further analysis.  
3.3.2 With NK-Cells (Degranulation and Cytotoxicity Assay) 
PBMCs were isolated as described above and consecutively NK-cells were separated with a 
CD56 isolation kit using autoMACs Pro Separator with the “depletes” program. Final cell 
numbers were assessed by Türks solution and cells were seeded out at a concentration of 
1x106 cells/mL in stem cell growth medium with 20% heat inactivated FBS and activated over 
night with 500 U/mL IL-2. 
 
NK mediated cytotoxicity was measured in a 51Cr-release assay with overnight IL-2 activated 
hNK-cells (effector cells) against unstimulated or 2 days IFN-g pre-stimulated (100 ng/mL) 
hESC-RPE. hESC-RPE (target cells) were labelled with 70 μCi 51Chromium for 1 hour at 37°C, 
NK-cells were then mixed with the labelled target cells at different effector:target ratios (10:1; 
3:1; 1:1; 0.3:1) in a 96-well plate and incubated for 4 hours at 37°C. After, supernatants (70 
μL) were transferred into 4 mL sample tubes and counted using a 2470 WIZARD2 automatic 
gamma counter. Percentage of specific lysis per sample type = [(experimental - spontaneous 
release) / (maximum load - spontaneous release) x 100].  
3.4 CRISPR-CAS9 GENOME EDITING 
CMV to EF1a promoter was exchanged into pX459 plasmid (addgene #62988) and in 
ampicillin-resistant TOP10 bacteria colonies, plasmid DNA was extracted using QIAprep Spin 
Miniprep Kit according to manufacturer’s instructions. Next, PNK treated sgRNAs were 
directionally cloned into plasmid pX459-EF1a, STBL3 bacteria were transformed and 
ampiciilin-resistant colonies were picked and expanded. Plasmid DNA was extracted using 
QIAprep Spin Miniprep Kit according to manufacturer’s instructions.  
HEK293T cells (in DMEM supplemented with 10% FBS, 0.1 mM NEAA, 6 mM GlutaMAX and 
1 mM Sodium Pyruvate) and hESC (HS980) were cultured to 70–80% confluency, and 
dissociated using TrypLE. The NEONTM Transfection System was used to electroporate 1 µg 
pX458_EF1a-Cas9_U6-sgRNA plasmid to a hundred thousand cells according to the 
manufacturer’s protocol. When confluent, cells were harvested for gDNA extraction and 
mutation detection. After 24 hours, puromycin (0.5 µg/mL) was used for selection for extra 24 
hours. For clonal expansion of hESC, once the cells reached 70–80% confluency they were 
dissociated, diluted and plated at a concentration of two cells per well in a 96-well plate 
previously coated with 15 µg/mL hrLN-521 and 1.7 µg/mL E-cadherin overnight. Single-cell 
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clones were cultured for further expansion and for genomic DNA extraction and Sanger 
sequencing of the region surrounding the edit. 
Genomic DNA extraction was performed using QuickExtractTM DNA extraction solution and 
1 µL of the extracted DNA was utilized for PCR amplification using Herculase II Fusion 
Enzyme. Mutation detection was performed using SURVEYOR Nuclease Assay according to 
the manufacturer’s protocol. Indel percentage was calculated with the following equation: 
100*1-√((1-((b+c))/((a+b+c)))), where a symbolizes the integrated intensity of the unedited 
DNA fragment, and b and c represent the intensities for each cleaved fragment.  
3.5 QPCR 
Total RNA was isolated using the RNeasy Plus Mini Kit from Qiagen and treated with RNase-
free DNase and RNaseH. Reverse transcription of RNA to cDNA was done using 1 μg of total 
RNA in a 20 μL reaction mixture using random hexamers and Superscript III enzyme. cDNA 
was preamplified using Taqman assays as primers in PCR reaction. Gene expression was 
quantified using Taqman assays and StepOnePlus Real-Time PCR system. Relative quantity 
was determined with comparative Ct (threshold cycle) method (2-ΔΔCt).   
3.6 FLOW CYTOMETRY 
hESC and hESC-RPE were dissociated into single cells using TrypLE as described above. 
Samples were stained using the following conjugated antibodies diluted in 2% FBS and 1mM 
EDTA DPBS or in Brilliant Buffer. Cells were incubated with the conjugated antibodies at 4°C 
for 30 min and washed twice with 2% FBS and 1mM EDTA diluted in DPBS. Fluorescence 
minus one (FMO) controls were included for each condition to gate negative and positive cells. 
7-AAD-PeCy5 or Zombie-APC-H7 NIR was added to the cells for Live/Dead stain according 
manufacturer instructions. Respective Geometric Mean Fluorescence Intensity (GMFI) values 
of the FMO controls were subtracted to obtain the final GMFI of each fluorophore. Stained 
cells were analyzed using a Cytoflex flow cytometer (Beckman Coulter). Analysis of the data 
was carried out using FlowJo v.10 software (Tree Star).  
3.7 WESTERN BLOT 
Total protein was extracted from cells by dissolving the collected cell pellet in cold radio-
immunoprecipitation assay (RIPA) buffer and protease inhibitors on ice for 5 min. After 
centrifugation at 2000g for 5 min, the protein concentration from the supernatant was 
determined by bicinchoninic acid (BCA) Protein Assay kit with BSA standards using 
NanoDrop. Protein was loaded on a 4-20% Tris-Glycine Extended gel after being incubated 
(denatured) in 1X Laemmli sample buffer supplemented with 2-mercaptoethanol, at 95°C for 
5 min. Following electrophoresis (120V for 70-80 min at room temperature), wet transfer (100V 
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for 60 min at room temperature) was carried out using an 0.2 µM PVDF membrane. 
Transferred blots were blocked using 3% BSA in 0.05% Tween-20 in DPBS prior to incubation 
with primary antibodies on a rotator at 4°C overnight. Secondary antibodies were incubated at 
room temperature for 1 hour using Alexa-680. The membrane was imaged using LI-COR 
Odyssey infrared imager (LI-COR). 
3.8 IMMUNOFLUORESCENCE 
Cells were fixed with 4% methanol free formaldehyde at room temperature for 10 min, followed 
by permeabilization with 0.3% Triton X-100 in DPBS for 10 min and blocking with 4% fetal 
bovine serum and 0.1% Tween-20 in DPBS for 1 hour both at room temperature. Primary 
antibodies were diluted to the specified concentrations in blocking solution, incubated 
overnight at 4°C. Secondary antibodies were incubated for 2 hours at room temperature and 
nuclei were stained with Hoechst. Images were acquired with a Zeiss LSM710-NLO point 
scanning confocal microscope and Olympus IX81 fluorescence microscope (Carl Zeiss 
Meditec). Post-acquisition analysis of the pictures was performed using ImageJ/Fiji software. 
3.9 TIME-LAPSE MICROSCOPY 
The Cell-IQ live imaging system (Chip-Man Technologies Ltd.) equipped with a 10x phase 
contrast objective, an automated stage and an integrated incubator (37°C, 5% CO2) was used 
to monitor hESC-RPE behaviour.After OVs dissociation, hESC-RPE were seeded in 
triplicates on the different substrates: 0.1% Gelatin, hrLN-111, -332, -511, and -521 (all 
20μg/mL). On day 1 after seeding, the plates were transferred to the live cell imaging 
equipment. Images were acquired for both the center (2x2 image grids) and the periphery 
(single images) of every well. Every region of interest was monitored every hour for 21 days. 
Cell migration (length and trajectory) was assessed for every time-lapse image stacks using 
NIS-Elements v.4.0 (Nikon). For each stack 10 cells were randomly chosen and manually 
tracked during the first 7 days of imaging.  
3.10 ELISA 
Supernatants from hESC-RPE or hESC-RPE and T-cell (either with CD8+ or CD4+ positive 
isolated PBMCs) co-cultures were collected 5 days after the cells were plated. Human VEGF, 
PEDF or IFN-g secretion levels were measured with commercially available ELISA Kits in 
accordance with the instructions of the manufacturers. The optical density readings were 
measured using SpectraMax i3x Reader (MolecularDevices).  
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3.11 PHAGOCYTOSIS ASSAY 
FITC-labelled bovine PR outer segments (POS) were isolated and kindly provided by Dr. E.F. 
Nandrot from Institut de la Vision, Paris (Parinot et al., 2014). hESC-RPE were cultured on 
Transwell membrane (0.33 cm2) coated with hrLN-521 20 μg/mL for one month after seeding. 
Cells were incubated at 37°C or 4°C for 16 hours with 2.42x106 thawed POS/Transwell diluted 
in DMEM or CO2 independent media, respectively. After incubation, cells were quenched with 
Trypan Blue Solution 0.2% for 10 min at room temperature, fixed with 4% methanol free 
formaldehyde at room temperature for 10 min and permeabilized with 0.3% Triton X-100 in 
DPBS for 15 min. Rhodamine phalloidin staining (20 min at room temperature) was used to 
visualize the cell boundaries. Nuclei were stained with Hoechst 20 min at room temperature. 
Images were acquired with Zeiss LSM710-NLO point scanning confocal microscope. Post-
acquisition analysis of the pictures was performed using IMARIS (Bitplane). 
3.12 TEER MEASUREMENTS 
RPE cells were plated on Transwells (0.33 cm2) and TEER was measured using the Millicell 
Electrical Resistance System volt-ohm meter (Millicell ERS-2), according to the 
manufacturer’s instructions. Cultures were equilibrated outside the incubator at room 
temperature for 15-20 min before the experiment. Measurements were performed in 
unchanged culture media at three different positions of each well. Averages were used for 
further analysis. The background resistance was determined from a blank culture insert in the 
same media coated with the corresponding substrate but without cells, and subtracted from 
the respective experiment condition. Measurements are reported as resistance in ohms times 
the area in square centimeter (Ω*cm2).  
3.13 RABBIT SERUM COLLECTION 
5-10 mL of blood was extracted from rabbits prior and after subretinal injections at different 
time points in serum collection tubes. The tubes were left in a standing position for about 15-
20 min until blood was clotted and they were then centrifuged at 20°C, 1500g for 10 min. 
Serum (supernatant) was quickly removed and stored at -80°C in 1 mL aliquots for further 
analysis.   
3.14 ANTIBODY-MEDIATED ASSAY 
100.000 cultured hESC-RPE were pelleted and mixed with 100 μL of serum for 30 min at room 
temperature. After two washes with 2% FBS and 1mM EDTA in DPBS at 300g for 5 min, 
secondary antibody donkey anti-rabbit was added for 20 min at 4°C and washed two extra 
times (300g, 5 min). Finally, 7-AAD-PeCy5 Live/Dead stain diluted in 2% FBS and 1 mM EDTA 
in DPBS was added to the cells. Stained cells were analyzed using a Cytoflex flow cytometer 
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(Beckman Beckman Coulter). Analysis of the data was carried out using FlowJo v.10 software 
(Tree Star). 
3.15 SUBRETINAL INJECTIONS IN THE RABBIT EYE 
hESC-RPE monolayers were washed with DPBS, incubated with TrypLE and dissociated to 
single cell suspension as described above. Cells were counted in a Neubauer hemocytometer 
chamber using 0.4% trypan blue, centrifuged at 300g for 4 min, and the cell pellet was 
resuspended in freshly filter-sterilized DPBS to a final concentration of 1000 cells/μL. The cell 
suspension was then aseptically aliquoted into 600 μL units and kept on ice until surgery.  
 
 
Animals were induced to general anesthesia by intramuscular administration of 35 mg/kg 
ketamine (Ketaminol 100 mg/mL) and 5 mg/kg xylazine (Rompun vet. 20 mg/mL), and the 
pupils were dilated with a mix of 0.75% cyclopentolate/2.5% phenylephrine. Microsurgeries 
were performed on both eyes using a 3-port 25G transvitreal pars plana technique. 25G 
trocars were inserted 1 mm from the limbus and an infusion cannula was connected to the 
lower temporal trocar (see setup in Figure 4). The cell suspension was drawn into a 1 mL 
syringe connected to an extension tube and a 38G polytip cannula. Without infusion or prior 
vitrectomy, the cannula was inserted through the upper temporal trocar. After proper tip 
positioning, ascertained by a focal whitening of the retina, 50 μL of cell suspension (equivalent 
to 50.000 cells) was injected slowly subretinally approximately 6 mm below the inferior margin 
of the optic nerve head, forming a uniform bleb that was clearly visible under the operating 
microscope. Care was taken to maintain the tip within the bleb during the injection to minimize 
reflux. After instrument removal light pressure was applied to the self-sealing suture-less 
sclerotomies. 2 mg (100 μL) of intravitreal triamcinolone (Triescence 40 mg/mL) was 
FIGURE 4. Subretinal pars plana injection 
set up in the rabbit eye.  
(A) Pictures depicting the surgical set-up for 
subretinal injections. The animal is placed 
under the surgical microscope (left) and the 
surgeon holds the endoillumination probe 
inserted through the left trocar, and the 
intravitreal surgical instrument (e.g. 
subretinal injection cannula) inserted 
through the right trocar (middle). A flat 
contact lens placed on the cornea allows a 
magnified view of the fundus during the 
surgical procedure (right). (B) Close 
schematic view of the albino rabbit eye with 
the lid retractor in place and the nipple from 
the trocars inserted 1-2 mm deep from the 
limbus and at a 30-45° parallel angle, 
together with the trocars that facilitate the 
introduction of an optional infusion cannula, 
the endoilluminator, and the needle for 
injection. (C) QR code linking to a video that 
illustrates the different steps of the 
procedure. Adapted from Petrus-Reurer et 
al., 2018.  
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administered a day prior to the surgery, and no post-surgical antibiotics were given. For the 
TCA cohort, intravitreal triamcinolone was re-administered every 3 months, if required.  
3.16 PHALLOIDIN FLATMOUNTS 
Immediately after euthanasia, the eyes were enucleated, and the injection area marked with 
Tissue Marking Dye (TMD). After removal of the anterior segment and vitreous, the posterior 
pole including the marked area was excised with a scalpel. After careful dissection of the 
neurosensory retina with a blunt spatula, the RPE– choroid–scleral flat-mounts were fixed in 
1.5 mL fixing solution (FS) overnight at 48°C. Postfixing, the tissue was extensively washed 
with PBS and stained with Hoechst and rhodamine-phalloidin. Staining was performed in PBS 
containing 0.1% Triton X-100 for 1 hour at room temperature under slow agitation. 
Subsequently, samples were extensively washed with PBS and flat-mounted in between two 
microscope slides with fluorescent mounting medium. Deconvoluted images of the RPE layer 
were obtained with a fluorescence microscope (Axioskop 2 plus using the AxioVision software, 
Carl Zeiss).  
3.17 HISTOLOGY 
Immediately after euthanization by intravenous injection of 100 mg/kg pentobarbital (Allfatal 
vet. 100 mg/mL), the eyes were enucleated and the bleb injection area marked with green 
TMD. An intravitreal injection of 100 μL FS consisting of 4% buffered formaldehyde was 
performed. FS remained for 24-48 hours followed by embedding in paraffin. 4 μm serial 
sections were made through the TMD-labeled area and every 4 sections were stained with 
hematoxylin-eosin.  
3.18 IMMUNOHISTOCHEMISTRY 
Slides were deparaffinized in xylene, dehydrated in graded alcohols, and rinsed with dH2O 
and Tris-buffered saline (TBS, pH 7.6). If the staining was performed using the Bond III 
instrument from Leica Biosystems/Leica Triolab AB the manufacturer’s instructions were 
followed and a pH 9.0 EDTA-buffer at 100°C for 20 min was used as antigen retrival. 
Otherwise, 10 mM citrate buffer (trisodium citrate dehydrate, pH 6.0) with 0.05% Tween-20 at 
96°C for 30 minutes was used, followed by 30 minutes in 10% normal donkey serum and 5% 
(w/v) protease free bovine serum albumin diluted in TBS. Primary antibodies were diluted in 
blocking buffer and were incubated overnight at 4°C. Secondary antibodies were diluted in 
blocking buffer and incubated 1 hour at room temperature; or in some cases, HRP-conjugated 
secondary antibodies were incubated for 30 min, followed by incubation with Tyramide Signal 
amplification Plus Fluorescein or Cy3 System from Perkin-Elmer. Sections were mounted with 
Vectashield with 4’,6-diamidino-2-phenylendole (DAPI) mounting medium in a 24x50 mm 
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coverslip. Images were acquired with a Zeiss LSM710-NLO point scanning confocal 
microscope and Olympus IX81 fluorescence microscope (Carl Zeiss Meditec). Post-
acquisition analysis of the pictures was performed using ImageJ/Fiji software.  
3.19 MULTIMODAL RETINAL IMAGING 
Anesthetized rabbits were placed in an adjustable mount. A commercial Spectralis HRA + 
OCT device (Heidelberg Engineering) with the Heidelberg Eye Explorer Software was used to 
obtain horizontal cross-sectional b-scans of hESC-RPE treated animals. The Spectralis has a 
real-time motion tracking system that minimizes eye motion artefacts. At least 3 cross-
sectional OCT scans were obtained with simultaneous infrared- confocal scanning laser 
ophthalmoscope (IR-cSLO) reflectance reference images representing the upper, central and 
lower portion of the transplanted area. The best overall image quality was obtained when the 
OCT setting was on high-speed acquisition with at least 50 averaged automatic real-time 
images. En-face fundus images were obtained by IR- or multicolor cSLO (a composite of three 
simultaneously acquired color cSLO images). These modalities have a higher contrast level 
compared to conventional fundus camera photos. In addition, corresponding BAF images 
were captured using the Spectralis blue light-laser with an excitation wavelength of 488 nm 
and a barrier filter of 500 nm.  
3.20 RETINAL MEASUREMENTS 
To measure retinal thickness (RT) and outer retinal thickness (ORT), SD-OCT images were 
imported into the ImageJ software. Retinal thickness and ORT are defined as the distance 
from the inner retinal surface to the RPE or from the inner nuclear layer to the RPE, 
respectively. 
For PR rescue analysis, ORT of treated regions was obtained from a section overlying at least 
500 μm of continuously integrated cells (mean of 10 random measurements). ORT of non-
treated control regions was obtained from the same scan 500 μm outside the bleb (mean of 5 
random measurements). Relative ORT was calculated as the ratio between treated and non-
treated retina. Distances were normalized to the 200 μm scale bar of the original image. All 
measurements were done in 14 injected eyes one month post-transplantation, or at the 
nearest time-point after (PAPER II). 
For subretinal PBS bleb-induced analysis, the thickness of untreated and treated retina was 
measured 500 μm from either side of the temporal transition zone of the bleb area. All 
measurements were made on a horizontal OCT scan through the temporal center of the bleb, 
approximately 6 mm below the margin of the optic nerve head. RT and ORT distances were 
normalized to the 200 μm scale bar of the original image. Ten consecutive measurements on 
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three independent OCT scans from 9 PBS-injected eyes (one month post-transplantation) 
were acquired (PAPER I).   
The relative IR-cSLO reflectance of subretinal blebs was estimated by using the histogram 
tool of the ImageJ software. The average pixel brightness was obtained by inserting a 
standardized circle (1 mm diameter) in the lower- right quadrant of the image immediately 
outside or inside of the injection area, respectively. The brightness ratio was then used as 
relative measure of bleb reflectance. Measurements were done in PBS- injected eyes in a 
time course of 28-days post-transplantation (PAPER I).  
The total area of the pigmented lesions was estimated manually on IR-cSLO images using the 
built-in measuring tool of the Spectralis software. Integration is defined as a pigmented area 
>2.5 mm2. Measurements were done in 14 injected eyes one month post-transplantation, or 
at the nearest time-point after (PAPER II); and in 5-14 eyes three- months post-transplantation 
(PAPER III), where also RPE atrophy (presence of hypo-BAF areas) was analysed either after 
one week and four months after initial PBS- or NaIO3- treatments (PAPER III).  
For subretinal/choroidal thickness measurements, SD-OCT scans were randomly made 
through the upper, middle and lower third of the subretinal lesions, and the scan with the 
largest subretinal infiltrate and simultaneous choroidal thickening was chosen for analysis. 
The height of the subretinal infiltrate (from the BM to the outer border of the neurosensory 
retina) was measured at the thickest point using ImageJ/Fiji. To obtain the value for choroidal 
thickening, the total thickness of the choroid was measured at the same position and 
subtracted from the choroidal thickness outside the bleb. Measurements were taken 7 days 
post-transplantation in 10-18 rabbit eyes (PAPER IV).  
3.21 STATISTICS 
Unpaired 2-tailed Student’s t-test was performed comparing RT and ORT in control and PBS-
treated eyes in PAPER I; and also comparing the relative ORT between eyes with integrated 
and with non-integrated hrLN-521-derived hESC-RPE in PAPER II. 
Unpaired 2-tailed Student's t-test and Chi-squared test were used to compare differences in 
hypo-BAF areas and incidence of RPE atrophy between PBS- and NaIO3- treated groups, 
respectively, in PAPER III; and to compare the different treatment groups in PAPER IV.  
In all cases, significance was accepted at p<0.05.  
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4 RESULTS AND DISCUSSION 
4.1 XENO-FREE AND DEFINED DERIVATION OF RPE FROM HESC (PAPER II) 
The development of an efficient protocol to derive RPE cells from stem cells is of major 
importance to have a reliable, pure and unlimited source of cells to transplant. Up to date, 
multiple protocols showed that RPE are possible to be obtained from different cell sources 
(hESC, iPSC) and using different strategies (spontaneous, directionally induced, xeno-free, 
defined). In Paper II we describe the spontaneous, xeno-free and defined derivation protocol 
we developed and the characteristics of the derived hESC-RPE.     
4.1.1 Methodology and hESC-RPE Characterization 
4.1.1.1 Results 
Confluent hESC cultured on hr-LN521 were firstly scraped to form embryonic bodies that after 
3 weeks in suspension in defined and xeno-free Nutristem media without bFGF developed 
pigmented structures resembling optical vesicles (OVs), with an efficiency of 0.8 OVs per EB. 
Secondly, pigmented OVs were mechanically cut out and the dissociated single cells were 
plated onto different substrates including gelatin, hrLN-111, hrLN-332, hrLN-511, hrLN-521 
(Figure 5). We show that hrLN-521 had the best plating efficiency and migratory properties 
together with hrLN-511, allowing the cells to cover the wells in a homogenous manner. 
Additionally, in all conditions, the plated OVs matured into pigmented hexagonal cells with a 
similar transcriptional profile including low expression of pluripotency associated transcripts 
(OCT3/4, NANOG), and strong expression of both neuroectoderm (SOX9, PAX6) and RPE-
differentiation transcripts (RPE65, PMEL, BEST1). Flow cytometry analysis showed that the 
derived cultures had a homogenous expression of MITF and BEST1 on all LNs compared to 
gelatin; and immunofluorescence showed a uniform expression of CRALBP and BEST1 with 
clear apical polarization of ZO-1 and Na/K-ATPase. At a functional level, hESC-RPE cultures 
showed polarized secretion of VEGF and PEDF as well as active phagocytosis of POS and 
tight junction integrity that got stronger over time determined by TEER measurements. For the 
latter, cultures on gelatin and hrLN-332 did not manage to reach that confluent stage.  
4.1.1.2 Discussion 
The establishment of a methodology that eliminates any undefined and animal-based products 
possibly contained in the differentiation process of hESC-RPE (e.g. media, substrate) is 
fundamental to avoid microbial contamination and presence of non-human proteins. In fact, a 
not defined final product could contribute to a faster rejection of the transplanted cells by the 
recipient immune system, which would mean the end of such replacement therapy. However, 
a recent 4-year report of a clinical trial leaded by Schwartz et al that used a batch of cells 
derived from hESC expanded on mouse feeders and further grown on gelatin and in non- 
 28 
defined media, showed no rejection or any other adverse effects of the transplanted allogeneic 
cells, although the patients were under a strong immunosuppressive regime (Schwartz et al., 
2016). In any case, a cleaner product could reduce the dose of immunosuppressant drugs 
given to the transplanted patients.  
Considering that our protocol relies on spontaneous differentiation and a more growth factor-
directed approach would avoid batch to batch variation, the efficiency in obtaining pigmented 
OVs is remarkably high compared to other xeno-free and spontaneous protocols (Lane et al., 
2014; Maruotti et al., 2013; Pennington et al., 2015), and in line with other more defined 
approaches (Choudhary et al., 2017; Hongisto et al., 2017; Idelson et al., 2009; Maruotti et al., 
2015; Osakada et al., 2009b). In addition to the manual dissection of pigmented OVs, our 
results show that the use of biologically relevant cell substrates is important for obtaining a 
homogenous mature and pigmented culture of hESC-RPE. In fact, the chosen laminins are all 
present in the BM, meaning that cells with properties resembling the native RPE cells 
expressing specific integrin subunits (e.g. a3, a6 and b1) will preferentially be selected over 
other cell types present in the OV in LN substrates compared to gelatin, therefore increasing 
the purity of the final product. Previous studies showed that LN511 and LN521 support the 
highest degree of migration (Aisenbrey et al., 2006), which could explain the observed 
advantage of hrLN-521 over the rest of the tested substrates. Of interest, the appearance of 
RPE cell pigmentation was induced by hrLN111 in a faster manner than with any of the other 
analyzed matrices, as also suggested previously (Rowland et al., 2013). Furthermore, it is 
FIGURE 5. Xeno-Free and Defined RPE Differentiation of hESC-RPE.  
(A) Scheme of the hESC-RPE differentiation protocol. Confluent hESC cultures are scraped and cultured in low-attachment plates 
to form EBs with Rock inhibitor during the first 24 hours. OV-like structures appear following week 3. At week 5, OVs are cut out 
with a scalpel and dissociated into single cells that are plated on hr-LN521 and cultured until homogeneous pigmentation is reached 
(week 9). Single-cell suspension of RPE cells are used for subretinal injection in the rabbit eye. (B) Representative picture of hESC. 
(C) Representative image of embryonic bodies and pigmented optic vesicles (arrow) after 3 weeks in suspension culture. (D) 
Representative picture of the derived hESC-RPE after 9 weeks in culture. Note the compacted monolayer of cobblestone pigmented 
cells. Adapted from Plaza Reyes et al., 2016. Scale bars: 100 µm. 
 
  29 
important to highlight that the expansion of cells in suboptimal conditions (e.g. gelatin, with 8% 
seeding efficiency compared to hrLN-521 with 69%) have the inherent risk of selecting for 
growth-promoting genetic abnormalities. In fact, single cell flow cytometry analysis of MITF 
and BEST1 revealed significant heterogeneity in gelatin (47/70% MITF/BEST1 positive cells) 
compared to the rest of the LN cultures (around 90/95% MITF/BEST1-positive cells). Finally, 
having a source of cells with the potential to mature and acquire functional characteristics 
similar to the native RPE (including morphology, RPE-specific marker expression, monolayer 
integrity, polarized growth factor secretion and phagocytic activity) implies that upon 
transplantation they might have better chances to integrate and restore the role of the 
damaged native cells.      
4.2 ESTABLISHMENT OF PRECLINICAL LARGE-EYED ANIMAL MODELS 
FOR GA (PAPERS I AND III) 
Up to date, genetic mouse models and RCS rats are the most commonly used models aiming 
to study advanced dry AMD (D'Cruz et al., 2000; Pennesi et al., 2012). These models usually 
exhibit a specific defective aspect involved in the pathology of complex nature, therefore 
implying that the field is lacking a model that faithfully recapitulates the phenotype of the 
human disease. Additionally, the use of rodent eyes is limiting in terms of imaging and surgical 
techniques, which differ from the clinical setup. Although pig or non-human primate eyes are 
closer to the human physiology and clinical approach, they require higher maintenance costs 
to be kept in reasonable numbers for the same time-span as other smaller animals. In Papers 
I and III we describe two models of retinal degeneration using the rabbit eye intending to 
develop a more suitable preclinical model for GA that is affordable and has the advantages of 
a large-eyed model of disease.    
4.2.1 Injection/PBS-Induced Degeneration Model (PAPER I) 
4.2.1.1 Results 
Following the human surgical retinal approach, a transvitreal pars plana technique was used 
to generate subretinal blebs of PBS or BSS in albino or pigmented rabbits. In addition, the 
same multimodal imaging (including SD-OCT, IR-cSLO and BAF) used in a clinical setup 
served to analyze the retinal phenotype. SD-OCT revealed 11 hyper- and hypo-reflective 
bands in the rabbit retina with clear delineation analogy to the human retina (Figure 6). In 
addition, the subretinal injection-induced outer retinal degeneration over the course of 28 days 
showing a demarked circular area in the bleb region with a hyporeflective margin and a 
hyperreflective center on MC and IR-cSLO, as well as thinning of the neurosensory retinal 
layers going from the outer nuclear cell layer to the outermost RPE/Bruch’s layer. In fact, the 
subretinal injection significantly reduced both total retinal and outer retinal thickness when 
compared to control eyes. This degenerative effect was persistent upon 12 weeks after 
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induction of the subretinal blebs, showed by IR-cSLO, SD-OCT and HE stainings. 
Furthermore, subretinal layers including RPE/Bruch’s also appeared to be affected as BAF 
revealed a “salt-and pepper-like” (hyper and hypofluorescent) pattern, and phalloidin-stained 
RPE flatmounts were indicative of a disturbed hexagonal RPE mosaic (Figure 7A). 
 
 
 
 
 
 
 
 
4.2.1.2 Discussion 
The large-eyed rabbit is a well-established ocular model with accumulated data on anatomy 
and physiology over the past centuries (Hughes, 1972). Moreover, rabbits are easy to handle 
and breed, and are economic (e.g. purchase, housing and maintaining) and readily available 
compared to other large-eyed mammal models. For all these reasons, rabbit eyes have been 
an instrumental model for the evaluation of the effects of new medical eye technologies and 
surgical procedures that are currently in practice (Prince, 1964). Here we report for the first 
time that multimodal imaging can be used in rabbits showing that their retinal anatomy is 
comparable to the human one. This multimodal imaging tool provides detailed morphologic 
information noninvasively and in real-time, therefore becoming a key instrument to study 
retinal degeneration or to optimize and monitor new treatments targeting the subretinal space. 
Specifically, we first show that the subretinal injection of PBS induces retinal damage in the 
large-eyed rabbit eye; and second, that this damage can be captured by the imaging 
modalities to show different aspects of retinal degeneration resembling human advanced dry 
AMD. These changes include: a gradual loss of the PR layers by time dependent thinning of 
the layers (SD-OCT) and demarked hyperreflection (IR-CSLO), and changes in the RPE layer 
indicated by hypo-BAF in the areas of injection.  
FIGURE 6. Normal albino rabbit retina in vivo multi-modal imaging.  
In vivo BAF, IR-cSLO, and SD-OCT images representing a normal albino rabbit retina. A magnification (white box) of the SD-OCT 
b-scans shows 11 distinct hyper- and hyporeflective retinal layers with similar retinal delineation to the human (lower SD-OCT 
images): GCL (ganglion cell layer), IPL (inner plexiform layer), INL (inner nuclear layer), OPL (outer plexiform layer), ONL (outer 
nuclear layer), OLM (outer limiting membrane), EZ (ellipsoid zone), OS (outer segments), RPE (retinal pigment epithelium), and BM 
(Bruch's membrane). Adapted from Bartuma et al., 2015. Scale bars: 1 mm (BAF and IR-cSLO), 200 µm (SD-OCT), 100 µm (SD-
OCT Rabbit, Human).  
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Despite lagomorphs being phylogenetically closer to humans than rodents, they possess a 
merangiotic retina and a visual streak in contrast to a holangiotic retina and a fovea present in 
primates (Blanch et al., 2012), thus meaning that that most of the blood supply of the inner 
rabbit retina is derived from the choriocapilaries. This morphological difference in 
vascularization could explain the neurosensitive retina degeneration phenotype seen in PBS-
injected rabbit eyes, which actually allowed for modelling of early stages of GA. In fact, bleb 
injection generates a retinal detachment that maintains the neuroretina without vascular 
support until the bleb resolves (which can take up to 2 days). This time without proper oxygen 
and nutrients could be a major factor causing the degeneration of the PR cells. However, the 
RPE layer do have a vascular supply right underneath the supportive BM. Therefore, the most 
plausible explanation behind the detected perturbed RPE layer (showed by hypoBAF and 
flatmounts) could be due to the mechanical pressure of the injection itself that would damage 
and even wipe out the native RPE cells, therefore causing their degeneration. Toxicity and 
injected volume could be two additional variables influencing in the retinal damage. However, 
PBS or BSS are physiologic salt solutions routinely used in eye care and should be non-toxic 
to the rabbit retina. We used a volume of 50 µL, which relative to the rabbit eye size is similar 
to the 100 µL volume used in macaque and to the 100-150 µL in current clinical cell therapy 
trials, which could result in more pronounced damage compared to larger volumes. Related 
to this and worth considering in the clinical situation is the injection-associated retinal damage 
for subretinal administration that could then have a direct detrimental effect on the already 
diseased PR and RPE layers.   
Overall, and despite the anatomical differences between rabbits and humans, the described 
model of injecting PBS in a merangiotic retina recapitulated some relevant features seen in 
human GA, including hypo-BAF and thinning of the outer retinal layers. However, a model with 
a more consistent damage in the RPE layer deserved additional exploration.   
4.2.2 Chemically/NaIO3-Induced Degeneration Model (PAPER III) 
4.2.2.1 Results 
In this study we further demonstrated that subretinal injections of PBS could induce a long-
term GA-like phenotype that consisted of two areas of damage seen by SD-OCT, histology 
and RPE65 immunofluorescence: an outer damage with hyper-BAF area with PR loss yet 
intact RPE layer, and an inner area of more profound damage shown by hypo-BAF and 
corresponding atrophic PR and RPE layers. In fact, PR loss and hyper-BAF were observed in 
all treated eyes, whereas the presence of hypo-BAF areas were rare. Therefore, in order to 
more specifically target the RPE, we injected NaIO3 subretinally in a dose-dependent manner. 
These injections showed that a dose of 0.1 mM caused changes similar to PBS alone (hyper-
BAF), whereas higher doses (1 and 10 mM) caused large areas of RPE degeneration (hypo-
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BAF) accompanied by a progressive loss of both the outer neuroretinal layer and the 
RPE/Bruch’s/choriocapillary complex demonstrated by SD-OCT, histology and RPE65 
immunofluorescence (Figure 7B). Doses of 10 mM caused further inner plexiform layer 
degeneration. In short, 1 mM NaIO3-injected eyes had a significantly higher frequency of areas 
with RPE loss than in PBS-injected eyes, therefore arising as a more consistent approach to 
induce degeneration of the neuroretina/RPE/choroid complex in the large-eyed model that 
also resembled clinical GA.  
4.2.2.2 Discussion 
The proposed NaIO3 model shows highly reproducible irreversible PR and RPE degeneration 
upon subretinal injection. As mentioned in the previous discussion, the mechanisms 
underlying neuroretinal and RPE cell loss are of different nature. The generation of a temporal 
subertinal bleb that induces retinal hypoxia in a merangiotic setup might be enough to cause 
PR death. However, since RPE do not detach from the choroidal support, the most likely 
explanation relies on the mechanical disruption induced by the injection itself, which is 
supported by the PBS model showing RPE loss in a limited fashion. Also, some recent reports 
showed that death mechanisms are different between PR and RPE, the former through 
apoptosis and the latter through necroptosis (Hanus et al., 2016), which could determine the 
different sensitivity of the cells to mechanical or chemical insults. Additionally, our data 
suggests that RPE loss accentuates neuroretinal death since the neurosensory retina present 
in hypo-BAF areas was more atrophic than in the hyper-BAF regions.  
The local administration of NaIO3 to induce retinal degeneration differs from conventional 
approaches that use a systemic route. Local subretinal injections are advantageous in the 
sense of having an adjacent healthy retina to compare to, in addition to studying an animal 
that is not under other possible systemic adverse effects of the chemical substance. 
Regardless of the administration route, several studies in rabbit, rodent and pig models 
confirmed the outer neuroretinal degeneration and RPE/Bruch’s damage that we also describe 
(Grignolo et al., 1966; Mones et al., 2016; Wang et al., 2014; Yang et al., 2014).   
Relevant to our model, and that genetically modified animals may lack, is the progressive 
structural PR and RPE damage showed by increasing hypo-BAF through time, in addition to 
PR thinning showed by histology and SD-OCT. This progressive model of disease can open 
a window to study the progression of the pathology under the same physiological conditions. 
However, the exact extend to which the injection/chemically-induced GA damage in the rabbit 
model corresponds to the GA damage caused by aging factors in humans remains to be 
assessed. For such evaluation, the aging variable should be incorporated to the model by for 
instance causing oxidative stress in the RPE cell layer with a 670 mm-laser light. Regardless, 
we demonstrate that the two models presented in this section induce many of the 
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characteristic changes of GA that current animal models fail to emulate, including 
degeneration of outer neuroretinal layer degeneration, RPE/Bruch’s complex and choroidal 
layers showed by well-defined hyperreflecrtive IR-cSLO areas, thinning of the PR layer on SD-
OCT and loss of RPE on BAF (Figure 7). Overall, PBS-induced changes were milder, 
mimicking an earlier disease phenotype; whereas NaIO3-induced changes related closer to 
end-stage GA with more extensive choroidal atrophy, and PR and RPE loss. 
 
FIGURE 7. Summary of the GA-like phenotypes upon subretinal injection of PBS or NaIO3.  
(A) Subretinal injection of PBS induced PR degeneration and RPE disturbance demonstrated by thinning of the neuroretinal layers in 
SD-OCT (A1 and A2), and hyper- and hypoflurescent dots in BAF (A1, dashed line) four weeks after injection. Arrows in A1 indicate 
total (black, from inner retinal surface to RPE/BM) and outer retinal (white, from INL to RPE/BM) thickness. Non-injected control retina 
is shown for comparison. (A3) Corresponding HE-stained histologic sections show gradual reduction of the ONL in the area of the 
subretinal bleb. The RPE, choroid, and sclera were lost during tissue processing and are not shown. (B) Subretinal injection of 1 mM 
NaIO3 induces PR and RPE loss demonstrated by thinning of the neuroretinal layers in SD-OCT (B1 and B2) and the 
RPE/Bruch’s/choriocapillaris layer (B1, closed arrowheads), and hypo-BAF areas (B1, dashed line) surrounded by hyper-BAF in the 
bleb area (dotted line) three months after injection. Non-injected control retina is shown for comparison. HE-stained (B3) and RPE65 
immunostaining (B4) of histologic sections show gradual neuroretinal atrophy, fusion with the underlaying layer and loss of the native 
RPE corresponding to areas of hypo-BAF. Note choroidal atrophy (B2, asterisk). The bleb margin (closed arrowhead) and border of 
RPE loss (open arrowhead) is marked in B2-B4. Adapted from Bartuma et al., 2015; and Petrus-Reurer et al., 2017. Scale bars: (A1, 
B1 BAF) 1mm; (A1 SD-OCT) 100 µm; (B1 SD-OCT, A2, B2) 200 µm; (A3, B3, B4) 100 µm.  
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Altogether, PBS/NaIO3 blebs in the rabbit eye induce damage that faithfully captures most of 
the pathology of clinical GA, therefore arising as a relevant preclinical model for investigating 
the restoring capacity of hESC-RPE. 
4.3 ASSESSMENT OF HESC-RPE INTEGRATION IN DEGENERATION 
MODELS FOR GA 
Transplantation of RPE cells derived from PSC as replacement therapy for advanced AMD 
aims to stop the progression of the disease and hopes for vision restoration. Currently, 
different approaches have been tested, either using iPSC or hESC-derived cells transplanted 
in mice, rats, pigs or non-human primate models of disease in sheets or in suspension with 
transcleral or transvitreal injection techniques. In Papers II and III, we describe the outcome 
of the transplanted hESC-RPE cells in suspension using a transvitreal pars plana technique, 
firstly in the injection-induced degeneration model (Paper II) and, secondly, after 7-days 
pretreatment either by injection or chemically-induced methods (Paper III).  
4.3.1 hESC-RPE Transplantation in the Injection-Induced Non-Pretreated 
Model (PAPER II) 
4.3.1.1 Results 
Albino rabbits were chosen to facilitate the tracking of the pigmented hESC-RPE on a 
transparent retinal background using multimodal imaging. Suspensions of hESC-RPE cells 
were transplanted into the subretinal space and after 1, 8 and 34-weeks histology and 
immunofluorescent stainings demonstrated that a monolayer of donor cells of human origin 
(NuMA positive) integrated in the host RPE layer overlaid by well-preserved PR. At eight 
weeks after transplantation, cells became heavily pigmented and acquired basolateral 
expression of BEST1. Remarkably, after 34-weeks donor cells were positive for the specific 
RPE marker RPE65 and showed cytoplasmic rhodopsin suggestive of maintained phagocytic 
activity. Additionally, eyes transplanted with hESC-RPE cells had significantly more preserved 
ONL and POS layers (seen in SD-OCT and histology) when compared to injected eyes that 
lacked or had minimal hESC-RPE integration (similar to PBS treatment alone), therefore 
rescuing their outer retinal thickness upon injection-induced damage. Finally, the 
transplantation of either hESC or fibroblasts formed transient cell aggregates that did not 
protect from the PR loss.   
4.3.1.2 Discussion 
Half of the transplanted human donor grafts in suspension after subretinal injections in the 
rabbit eye model showed hESC-RPE integrated patches of at least 2.5 mm2, which is 
considered an excellent outcome for xeno-transplantation. The specific mechanism of PR 
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rescue by the integrated hESC-RPE (protective effect) is not clear and would most likely differ 
from the human setting due to the species-anatomical differences. However, a plausible 
hypothesis in the rabbit model could be that upon retinal detachment due to the subretinal 
bleb, integrated hESC-RPE provide the necessary support when the retina reattaches; 
whereas if not present and the native RPE cells have been denuded or are unhealthy, the 
hypoxic-survivor PR are left without the cells that would support and connect them to the 
choriocapillary bed, therefore leading to their degeneration.  
Failure of integration frequently correlated with signs of immunoreaction, including cell 
infiltration, retinal atrophy and donor cell loss. Thus, xeno-graft rejection indeed might be the 
most probable explanation for the variability between animals and between eyes of the same 
animal, which will then require a more optimized immunosuppressive protocol. Actually, the 
use of a transvitreal approach to inject the donor cells compared to a transcleral surgery (used 
mostly in rodent injections) that would disrupt the blood-retinal barrier should reduce the risk 
of triggering an inflammatory response. Another factor that could contribute to a better 
integration could be the native state of the injected cells with certain adhesion or survival 
properties. In fact, a previous study showed that an intermediate state of differentiation (week 
4 after passaging and differentiation of RPE stem cell-derived RPE cells from donor eyes) had 
the best integration and vision rescue outcome in the RCS rat model (Davis et al., 2017), which 
could correlate with our day 30 cells after OV dissociation. However, further experiments 
injecting hESC-RPE at different maturity stages in our model could shed some light in this 
matter. Interestingly, hESC-RPE de-pigment and de-mature upon trypsinzation (thus making 
the exact differentiation state of the injected cells unclear) possibly via an epithelial-to-
mesenchymal transition, which should make them more migratory and maybe better equipped 
for integration. Then, re-acquisition of tight junctions and maturation/pigmentation –including 
down-regulation of activating molecules (e.g. HLA-II) or secretion of immunosuppressive 
factors (e.g. TGFb or PEDF), is crucial to avoid immunoreaction and to increase survival of 
the integrated cells. Additionally, a not completely denuded native RPE cell layer could also 
affect integration of the donor cells to the host BM. For this reason, transplantation of hESC-
RPE in pretreated animals with either injection or chemically-induced retinal degeneration 
merited further evaluation and will be discussed in the next section. 
Interesting to note is the number of cells used for transplantation, which for the rabbits was 
50.000 cells/50 µL compared to the high concentrations injected in rodents, typically 50.000 
cells/1 µL in a three-times smaller eye. This made our surgical approach more controlled and 
with less chances of having multilayering and clumping of cells. In fact, some studies in rodents 
have shown that PR rescue was neither RPE-specific nor correlated with an intact donor cell 
layer (Pinilla et al., 2009). 
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Finally, the transplantation of hESC-RPE in the injection-induced large-eyed model could be 
performed with a surgical technique and instrumentation that was identical to a clinical setting, 
and could be monitored through time with high-resolution imaging techniques. In addition, and 
despite possible rejection of the xeno-transplant, we showed that hESC-RPE could integrate 
forming monolayers ten-times the size of a conventional RPE sheet for up to eight months, 
maintaining functionalities of native RPE cells and with ability to rescue PR from injection-
induced degeneration in a specific and sensitive manner, where both non-RPE and non-
integrated RPE cells were ineffective. The correlation of the hESC-RPE integration in the 
rabbit versus a human setting is unclear, and can only be tested with human subjects and 
allogeneic cells. 
4.3.2 hESC-RPE Transplantation in the Injection/PBS- or Chemically/NaIO3-
Induced Pretreated Models (PAPER III) 
4.3.2.1 Results 
Firstly, hESC-RPE transplantation in non-pretreated naive eyes formed extensive pigmented 
subretinal monolayers correctly placed in between PR and Burch’s membrane and not 
overlaying with native RPE cells. Notably, after 3 months, hESC-RPE cells were not found in 
areas of outer retinal degeneration and native RPE loss but instead in adjacent areas overlaid 
with well-preserved PR. Secondly, a pretreatment model for GA was induced by subretinal 
injections of either PBS or NaIO3 7-days prior to hESC-RPE transplantation at the same site 
where the initial bleb was located. For the PBS pretreated eyes, SD-OCT and BAF images 
taken before transplantation confirmed loss of PR layers. After 3 months, hESC-RPE were not 
found integrated but occasional pigmented dots or hyperreflective patches indicative of donor 
cells could be detected by cSLO, SD-OCT, histology and RPE65 immunostaining. For the 1 
mM NaIO3 pretreated eyes, SD-OCT and BAF before reinjection confirmed loss of PR layers 
as well as presence of hyper- and hypo-BAF. However, after 3 months, no trace of hESC-RPE 
was observed by either cSLO or SD-OCT (see summary in Table 1). Overall, these results 
suggest that hESC-RPE in suspension cannot integrate in areas of pre-induced retinal 
damage but instead in areas with a well-conserved outer neuroretina/RPE complex.  
TABLE 1. Summary of the integration outcome of the transplanted hESC-RPE into the injection-induced (PBS) or 
chemically-induced (NaIO3) GA-like damage models.  
Adapted from Petrus-Reurer et al., 2017. 
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4.3.2.2 Discussion 
Transplantation of hESC-RPE in the injection-induced model formed extensive functional 
monolayers. However, in some instances integrated hESC-RPE cells were only found in the 
boundaries of a more pronounced damage overlaid with a well-preserved PR layer. This 
observation suggests that donor cells should be able to integrate if several variables come 
together: (i) native RPE cells are denuded (due to injection or chemical toxicity) to create space 
for the donor cells; (ii) mechanical pressure of the injection does not affect the BM so the cells 
have a matrix to attach to; and (iii) immune infiltration remains controlled by the 
immunosuppressive dose so the grafted cells are not rejected. Therefore, if any of these 
conditions is not fulfilled, integration in a xeno-model fails. Actually, the fact that denudation of 
the native RPE layer (especially with the NaIO3 pretreatment) did not improve hESC-RPE 
integration into the host tissue as other studies have shown (Carido et al., 2014) is puzzling. 
Possible explanations include: rejection of the cells before they reached the integration side, 
or/and severe damage in the RPE/Bruch’s complex due to injection or/and NaIO3 toxicity, 
which would have impeded donor cell attachment. To be able to rule out one or the other, new 
experiments with a more controlled host immune system will need to be performed (e.g. 
different doses or types of immunosuppressant or use of immune-evasive cells). Interestingly, 
in the PBS pretreatment model we showed that RPE atrophy was significantly less present 
than in NaIO3 pretreated eyes, and that some traces of hESC-RPE cells could still be found 
integrated. Putative explanations of the poor yet traceable integration in the PBS pretreatment 
model compared to NaIO3 could be that: (i) native RPE were denuded but not sufficiently by 
the subretinal injection of PBS (in fact donor hESC-RPE were surrounded by native RPE 
positive for RPE65); (ii) the RPE/Bruch’s complex was affected by the injection itself in the 
PBS model but still to a milder degree than in NaIO3 treated eyes (injection in addition to 
chemical exposure); or/and (iii) the immune reaction might have been present in both cases 
but at a different rejection phase, so total clearance of the injected cells in the PBS pretreated 
model was not yet reached. In summary, in this study, the notably low-null rate of hESC-RPE 
integration could be a consequence of the unique features of the rabbit eye, the nature of the 
induced degeneration (PBS or NaIO3) or the immunosuppressive regime. Despite that, we 
observed that hESC-RPE in suspension could integrate properly only if the subretinal milieu 
is sufficiently preserved, regardless of the initial status of the neuroretina; and again, the 
neuroretina was conserved if the RPE layer was not impaired.  
In addition, it should be considered that pretreated areas were injected twice therefore 
increasing the risk of mechanical disruption of the outer blood-retina barrier that could trigger 
an immune response. This observation is critical to consider when transplanting hESC-RPE 
into pathologic eyes lacking a properly functional blood-retina barrier, since they will probably 
be more susceptible to immune reactivity. This double injection also causes a second round 
of neuroretinal detachment from the blood supply (in addition to the induced or chemical 
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damage generated with the pretreatment injection) as discussed above, thus adding an extra 
layer of challenge to the transplantation success.   
Having all this in mind, if successful repopulation of hESC-RPE is to be achieved in areas of 
extensive outer neuroretina/RPE/Bruch’s atrophy, the implementation of sheets of polarized 
hESC-RPE with or without supportive biomatrix or the use of hydrogels that could help RPE 
attachment in a damaged Bruch’s should be considered. However, it will be important to 
optimize the sheet technology, as surgical difficulties and potential immunological response to 
the transplant leading to outer retinal atrophy in large-eyed animals have been reported 
(Ilmarinen et al., 2015; Stanzel et al., 2014). 
Finally, our preclinical data suggests that suspension transplants of hESC-RPE may have the 
capacity to functionally repopulate the area outside the GA but not the GA area itself, as shown 
also by Schwartz et al in preliminary data from the first clinical trial on hESC-RPE in GA 
patients (Schwartz et al., 2016). Therefore, for the suspension approach to be functionally 
effective (i.e. stopping the progression of the disease and maintaining the remaining PR alive), 
it will be crucial to choose patients diagnosed in an early stage of the disease with a relatively 
conserved outer retina.  
4.4 GENERATION AND IMMUNOLOGICAL EVALUATION OF HLA-I KNOCK 
OUT HESC-RPE (PAPER IV) 
Avoiding the rejection of a transplanted graft by the host immune system is essential for the 
success of any allogeneic stem-cell based replacement therapy. Several immune escape 
approaches have been suggested, such as the use of iPSC cells, PSC-banking of HLA-
homozygous superdonors or the establishment of a universal line lacking the HLA molecules 
that would identify the donor cells as foreign. In Paper IV we first describe the generation of a 
HLA-I knock out (KO) hESC line that is further differentiated into hESC-RPE and, second, we 
evaluate its immunological properties in vitro after co-culture with T- and NK- cells, and in vivo 
after subretinal transplantation in the large-eyed rabbit model.     
4.4.1 In Vitro Characterization of hESC-RPEB2M+/+ and hESC-RPEB2M-/- 
4.4.1.1 Results 
The B2M locus was targeted using CRISPR-Cas9 technology with a sgRNA cutting efficiency 
of approximately 40%. IF, WB and flow cytometry confirmed that the B2M-targeting generated 
a dysfunctional HLA-I protein that was not able to be presented to the cell surface but was still 
present intracellularly. Engineered hESC were further differentiated into hESC-RPE that 
maintained pigmentation, morphology and immunosuppressive characteristics of native RPE 
cells but also lacked the extracellular expression of HLA-I. Interestingly, 20- or 50-times less 
hESC-RPE cells than PBMCs in a stimulatory environment (2 day 100ng/mL IFN-g pre-
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stimulation of hESC-RPE, and IL-2+CD28 added to the co-cultures) was sufficient to generate 
a 4-fold increase in CD8+ T-cell proliferation compared to PBMCs only. Subsequently, co-
culture of hESC-RPE with isolated CD8+ or CD4+ T-cells at selected ratios showed a clear 
reduction in the levels of IFN-g (as measure of T-cell activation) especially secreted by CD8+ 
T-cells when hESC-RPEB2M-/- were present. Analysis of specific T-cell ligands in both hESC 
and hESC-RPE genotypes showed that PD-L1 was highly expressed in all lines by either 
unstimulated or 2/5-days IFN-g stimulated cells. In addition, about 5% of the hESC-RPE cells 
were able to express co-stimulatory ligand CD80 if stimulation was present. When co-cultured 
with freshly isolated NK-cells, chromium assay revealed that hESC-RPEB2M-/- were more 
susceptible to NK killing than hESC-RPEB2M+/+ and that 2-days 100ng/mL IFN-g pre-stimulation 
of hESC-RPE notably reduced the cytotoxicity levels in both lines. Additionally, we also tested 
if the maturity of the hESC-RPE cells could have an effect in NK killing, and both hESC and 
younger hESC-RPEB2M+/+ (d14-d20) were more targeted than more mature hESC-RPEB2M+/+ 
(d25-d33). Further analysis on the NK-cell ligands showed that all HLA molecules were 
downregulated in unstimulated or 2/5 days IFN-g stimulated hESC-RPEB2M-/-. PCNA 
(upregulated during cell stress and recognized by the activating NK-cell receptor NKp30) and 
MICAB (upregulated during proliferation and recognized by the activating NK-cell receptor 
NKG2D) were poorly detected in both hESC-RPE lines, but the latter was especially up-
regulated on 5-days stimulated hESC cultures. CD112 (a ligand for the activating receptor 
DNAM-1 and the inhibitory receptor TIGIT) was highly expressed in all cell types and 
conditions, and CD155 (another ligand for DNAM-1, TIGIT and CD96, ascribed with both 
activating and inhibitory functions) was upregulated in higher levels in 2/5-days IFN-g 
stimulated hESC and hESC-RPEB2M+/+ compared to hESC-RPEB2M-/-.  
4.4.1.2 Discussion 
The use of CRISPR-Cas9 technology has recently emerged as an efficient and easy approach 
to create targeted point mutations in specific genes of interest that due to inaccurate DNA 
repair lead to a defective protein. In fact, targeting the B2M locus using this technology is the 
way we generated the HLA-I KO hESC line described in this study. However, one of the 
limitations of this method is the potential off-target sequences that might emerge from 
unspecific guide-binding. Although in our case, neither hESC nor hESC-RPE showed impaired 
native characteristics, a more detailed analysis of the mutations present in the engineered 
sequences needs to be assessed by whole-genome DNA sequencing.  
The observed immunosuppressive capacity of hESC-RPE could be due to the secretion of 
PEDF, TGFb3 or IL-10, or the expression of CD95 or PD-L1 ligands (Idelson et al., 2018; 
Sugita et al., 2010; Sugita et al., 2009b; Usui et al., 2008; Wenkel and Streilein, 2000; Zamiri 
et al., 2006), the latter also suggested by our data. However, it is worth considering that in the 
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pathologic retina (e.g. altered blood-retina barrier, BM or/and the RPE), this 
immunosuppressive capacity might be altered promoting a more immune-susceptible 
subretinal space. Thus, the use of an optimized dose of immunosuppressants or a less 
immunogenic graft would be desirable for an allogeneic transplant. 
In vitro co-cultures of T-cells and hESC-RPE in a specific RPE:immune cell ratio, together with 
inflammatory/stimulatory molecules such as IFN-g or IL-2, showed that the lack of HLA-I 
(hESC-RPEB2M-/-) reduced CD8+ T-cell activation measured by IFN-g production; therefore 
confirming that foreign antigens presented via HLA-I molecules could trigger cytotoxic T-cells 
and acute graft rejection. Of interest is the fact that approximately 5% of the hESC-RPE cell 
population under IFN-g stimulation up-regulated the co-stimulatory ligand CD80, implying that 
T-cell mediated immune reaction could be triggered without APCs.  
When co-cultured with NK-cells, our data showed that the “missing self” phenotype of the 
hESC-RPEB2M-/- more potently triggers an innate cytotoxic NK response than the mismatched 
HLA-I present in hESC-RPEB2M+/+. This killing could be mediated by the CD112 ligand for the 
activating receptor DNAM-1 which appeared highly up-regulated, as has been previously 
demonstrated (Cerboni et al., 2014; Dressel et al., 2010; Kruse et al., 2015). Interestingly, 2-
days IFN-g stimulation decreased the cytotoxicity levels in both lines, which could be due to 
the up- or down-regulation of certain inhibitory ligands that would block the NK action. A 
potential candidate that we have not evaluated is HLA-E, which has been incorporated into 
hESC by other groups to avoid innate immune system-mediated rejection (Gornalusse et al., 
2017; Sugita et al., 2018). Another candidate could be CD155 since it was found to be down-
regulated in hESC-RPEB2M-/- compared to hESC-RPEB2M+/+ under stimulatory conditions. In line 
with other studies that propose both activating and inhibitory functions of this ligand (binding 
to either the activating receptor DNAM-1 or the inhibitory receptors TIGIT and CD96 (Bottino 
et al., 2003; Chan et al., 2014; Georgiev et al., 2018; Levin et al., 2011; Stengel et al., 2012; 
Tahara-Hanaoka et al., 2004)), our data suggests a potential dual role of CD155 also inhibiting 
NK cytotoxicity. Further investigations with KO lines for CD155 would be required to identify 
its specific effects.     
Another critical observation of our results is that the maturation stage of the cells influences 
the NK cytotoxic activity, since hESC and younger hESC-RPEB2M+/+ (below day 20) were more 
killed than older hESC-RPE (above day 25). This could be related to the consolidation of a 
more mature RPE phenotype (e.g. secretion of growth factors and stabilization of tight 
junctions), which could also involve up-regulation of NK inhibitory ligands in more mature cells, 
or down-regulation of activating NK ligands in younger cells. Further studies on the specific 
ligands expressed in each time point should provide some insight on this maturation-
dependent differences in cytotoxicity. This may have critical implications in future 
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transplantation studies since younger cells may integrate better but also become rejected 
more easily.  
 
Several considerations to bear in mind with the use of hESC-RPEB2M-/- cells include: whether 
the lack of HLA-I molecules will make them unrecognizable by the host immune system with 
increased risk of tumor formation or infections. Therefore, a fail-safe/suicidal cassette system 
integration enabling the elimination of the engineered cells upon administration of a specific 
drug should be considered. Additionally, the presence of sugars, minor antigens that do not 
require HLA molecule presentation or pieces of dead grafted cells could also be a source of 
recognition by APCs that could start an immune reaction. In this case, low doses of 
immunosuppressants will still be needed.  
 
In summary, our data shows that hESC-RPEB2M-/- have the potential to partially escape the 
adaptive immune system, especially when CD8+ T-cells are involved. However, cells lacking 
both HLA-I and HLA-II molecules would avoid both CD4+ and CD8+ T-cell recognition. In this 
case, the innate immune system (including NK-cells) may still be activated, thus requiring the 
integration of specific NK inhibitory ligands such as HLA-E, as discussed above.  
4.4.2 Transplantation of hESC-RPEB2M+/+ and hESC-RPEB2M-/- in a Xenograft Model 
4.4.2.1 Results 
Cell infiltration from subretinal hESC-RPEB2M+/+ transplants in non-immunosuppressed and 
TCA-treated animals was analyzed by real-time multimodal imaging through time. Grafts 
under TCA displayed homogenous monolayer integration evidenced by IR-cSLO and SD-
OCT. However, in most cases at later time points, SD-OCT revealed a pronounced mass in 
the subretinal space displacing the pigmented donor cell layer accompanied by a thickening 
of the choroid, and eventually leading to an atrophic retina and choroid. Histological analysis 
confirmed a dense packed subretinal infiltrate with mononuclear and inflammatory cells. 
Further tissue stainings of the infiltrated areas revealed that rabbit immune cells from both the 
innate (NK-cells: CD56+, macrophages: RAM11+) and the adaptive (T-cells: CD3+) immune 
system were present at different rejection stages compared to non-rejected eyes. Interestingly, 
HLA-I was expressed in grafted cells also in later stages with deteriorated cell integrity, and 
HLA-II only appeared positive in cases of pronounced rejection. Rejection was shown in all 
non-immunosuppressed eyes within one week post-transplantation; whereas in TCA-treated 
animals, subretinal infiltration was seen rarely after one week, only in half of the transplanted 
eyes after one month, and in most of the eyes after three months.  
Subretinal injections of hESC-RPEB2M-/- in non-immunosuppressed animals showed no signs 
of rejection in almost half of the transplanted eyes after one week, also in accordance with 
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both choroidal and subretinal thickness measurements at that time point that showed 
significant decrease compared to hESC-RPEB2M+/+. The addition of TCA did not further reduce 
rejection in hESC-RPEB2M-/- transplanted eyes after 90 days. We also analyzed the amount of 
anti-human antibodies present in rabbit serums collected at different time-points before and 
after injection. Without TCA treatment, anti-human antibodies were already detected one week 
after hESC-RPEB2M+/+  transplantation, whereas in hESC-RPEB2M/- transplanted animals, they 
appeared after two weeks in two-fold lower amounts compared to hESC-RPEB2M+/+. With TCA 
treatment, anti-human antibody levels were not detected after one week, and they were 
present in low amounts (compared to hESC-RPEB2M+/+ without TCA) after two weeks. Anti-
human antibodies were detected in all the conditions analyzed after one and three months. 
4.4.2.2 Discussion 
A first aspect to be considered in our study is the use of a xenogeneic rabbit model, which 
resulted in rapid rejection of the grafted human cells, especially if immunosuppression was not 
administered. However, in a comparable clinical setting, the donor cells would be allogeneic 
and rejection would be expected to be less prominent. Thus, any reduction in rejection 
identified in the xenogeneic model should also be expected to translate into the human 
allogeneic setting.  
 
Without immunosuppression, hESC-RPEB2M+/+ donor cells triggered rapid rejection, whereas 
TCA delayed and in some cases impeded rejection. The rejection stages presented in this 
study for hESC-RPEB2M+/+ cells are categorized depending on the level of retinal infiltration and 
atrophy, which do not necessarily correlate with time since local factors might be involved. In 
fact, immune reaction is highly dependent on the degree of damage of the BM and the blood-
retinal barrier that would allow the host immune system to infiltrate in the grafted area, with 
determinant consequences for donor cell integration, as discussed in previous sections. Our 
data shows that the type of infiltrating cells present in these eyes belong to both innate and 
adaptive immune systems in all stages of rejection, which might be explained by the host-
donor species difference. Evaluation of the specific type of T-cells present (CD8+ or CD4+ or 
both) in the infiltrations deserves further exploration since a reduction in CD8+ T-cells would 
be expected after hESC-RPEB2M-/- transplantation.  
 
Transplantation of hESC-RPEB2M-/- showed a reduced acute inflammation in both the 
subretinal and choroidal spaces, and delayed the appearance of anti-graft (human) antibodies 
compared to hESC-RPEB2M+/+. This suggests that early immune reaction might be triggered 
by HLA-I antigens recognized by the host innate (NK-cell) and adaptive (CD8+ T-cell) immune 
system. Interestingly, the addition of TCA immunosuppression did not further reduce rejection 
of hESC-RPEB2M-/- transplanted eyes and rejection was still observed through time, which may 
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be due to antibodies produced against human cells via indirect allorecognition by APC 
(macrophages, dendritic cells, lymphocytes B) through mismatched HLA-II if up-regulated, or 
the presence of minor antigens or other cell surface proteins/sugars. Any of these events will 
lead to CD4+ T-cell activation, B-cell maturation and antibody production contributing to 
delayed graft rejection. 
 
In brief, although it is clear that hESC-RPE can induce both adaptive and innate 
immunoresponses in vitro and in vivo, the lack of HLA-I molecule showed a reduced and 
delayed immune response to the xenograft which may translate into better survival of a human 
allograft (see summary in Table 2). This would in turn reduce the need for immunosuppressive 
drugs. Altogether, hESC-RPEB2M-/- are the first step towards universal donor cells for cell 
replacement therapy in AMD and related conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 2. Summary of the in vitro and in vivo techniques used and results obtained to study the immunogenic 
properties of hESC-RPEB2M-/-  and hESC-RPEB2M+/+. 
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5 CONCLUSIONS 
In this thesis we established a xeno-free and defined protocol to derive RPE cells from hESC. 
In addition, we took advantage of the surgical and retinal high-resolution imaging techniques 
that the large-eyed rabbit eye offers to develop a preclinical model of GA that faithfully 
emulates the pathological characteristics of clinical GA. We also assessed the integration 
capacity of the derived hESC-RPE into such models of disease. Finally, we developed a 
CRISPR-Cas9 based immune escaping strategy to avoid rejection of the grafted donor hESC-
RPE cells into the host retinal tissue.   
The main findings of these studies are: 
• The spontaneous xeno-free and defined protocol allowed the efficient derivation of 
hESC-RPE cells that exhibited characteristics of native RPE cells, including 
morphology, pigmentation, marker expresssion, monolayer integrity and polarization 
together with phagocytic activity.  
• hrLN-521 not only elimininated the need for undefined or xeno-derived matrix 
components but also emerged as a more supportive culture substrate for the derivation 
of hESC-RPE. 
• The large-eyed rabbit model allowed the use of noninvasive high-resolution and real-
time imaging techniques in addition to surgical techniques identical to a clinical setting.  
• Subretinal injections of PBS or NaIO3 in the rabbit eye induced damage that faitfully 
captured most of the pathology of clinical GA: PBS-injection (injection-induced) 
mimicked an earlier disease phenotype with loss of PR layers on SD-OCT and hyper-
and hypo-BAF of the RPE; NaIO3-injection (chemically-induced) mimicked end-stage 
GA with choroidal atrophy, more extensive loss of outer retinal layers and hypo-BAF 
areas of RPE loss.   
• Suspension transplants of hESC-RPE using a minimally invasive surgical procedure 
in the large-eyed disease model achieved high-yield functional long term hESC-RPE 
integration with PR preservation in the injection-induced non-pretreated model.  
• In the PBS/NaIO3 pretreated model, suspension transplants of hESC-RPE did not 
integrate in areas of profound GA damage but did integrate only if the subretinal milieu 
was sufficiently preserved.  
• hESC-RPE lacking HLA-I could be generated by targeting the B2M locus using 
CRISPR-Cas9 technology. 
• Both hESC-RPEB2M+/+ and hESC-RPEB2M-/- had an immunosuppressive ability but 
under specific ratio and stimulatory conditions they both triggered T-cell proliferation.  
• Under stimulatory conditions, hESC-RPEB2M-/- significantly reduced CD8+ T-cell 
activation and consequent IFN-g production; and upon mixing with NK-cells hESC-
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RPEB2M-/- triggered a higher cytotoxic response than hESC-RPEB2M+/+, which was 
reduced for both cells types if pretreated with IFN-g for 2 days.  
• Mature hESC-RPEB2M+/+ (above 25-days) exhibited less NK cytotoxic effect than hESC 
or younger hESC-RPEB2M+/+ (below 20-days).  
• In the large-eyed model, transplantation of hESC-RPEB2M+/+ without TCA showed 
rejection within one week with infiltrates from both the innate and adaptive immune 
systems at all stages of rejection; whereas transplantation of hESC-RPEB2M-/- showed 
a reduced acute early inflammation in the grafted areas and surrounding vascular bed 
and a belated appearance of a anti-human antibodies, overall delaying the rejection 
appeareance over time. 
• The addition of TCA immunosuppression did not further reduce rejection of hESC-
RPEB2M-/- transplanted eyes over time.  
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6 FUTURE PRESPECTIVES AND CHALLENGES 
In the past ten years, stem cell-based treatments for the advanced forms of AMD have 
translated into preclinical and clinical studies at a vertiginous speed. However, in order to grant 
a safe and efficient therapy, the evaluation of the challenges entailed to bring these therapies 
into the bedside is of critical importance.  
Briefly, such concerns and obstacles can be summarized in the following points (Nazari et al., 
2015) (Figure 8): (i) development of sources of RPE and retinal progenitors that are low cost, 
reliable, robust enough, and able to be expanded and commercialized; (ii) optimization of the 
methods to deliver stem cell derived-RPE into the subretinal space in an efficient manner; (iii) 
long-term survival and function of the implanted cells; (iv) long-term safety of the procedure 
and the cells, assuring the inexistence of any type of tumor formation at any time after 
transplantation; (v) methods to minimize the risk of immune rejection of the transplanted cells; 
(vi) election of the optimal timing for transplantation considering risk-benefit for the patient; (vii) 
assessment if the replacement therapies slow the progression of the retinal degeneration or 
factually improve vision by integrating into the host retina and restoring retinal function.  
 
 
 
 
 
 
 
The studies described in this thesis work aimed to acquire novel knowledge in several of the 
before mentioned aspects to transit to the bed side in the most efficient and safe manner.  
Firstly, we describe the derivation of functional RPE cells from hESC utilizing a spontaneous 
xeno-free and defined protocol which should avoid any immune reaction due to non-human 
proteins; however, a more directed approach would improve the batch to batch variability and 
would make it more suitable to scale up. Of note, progress in the mobilization of adult tissue-
specific retinal stem cells or the reprogramming of Müller glial cells into a retinal neuronal fate 
FIGURE 8. Diagram that 
recapitulates the main steps 
towards a stem-cell based 
therapy for the treatment of GA.  
The panels highlighted with an 
exclamation mark summarize 
possible concerns and challenges 
of the stem cell-based treatments. 
  
 48 
in vivo would simplify the technical complexities of the approaches that are currently in clinical 
stage (Coles et al., 2004; Zhao et al., 2014). Additionally, the derived cells should be tested 
for acquired pathogenic mutations by whole-genome DNA sequencing, and also 
tumorigenicity and biodistribution studies should be carried out in the appropriate animal 
models (International Stem Cell, 2018). In fact, these studies have been pursued already in 
our lab showing that the derived cells appeared safe in all the performed tests. Moreover, the 
use of specific cell surface markers differentially expressed in hESC-RPE could serve as a 
quality control of the purity of the final product, but also as an enrichment method for hESC-
RPE upon RPE induction (Choudhary and Whiting, 2016).  
Secondly, we describe the development of two large-eyed models that recapitulate the 
characteristics of clinical GA, in earlier or later stages, by multimodal retinal imaging and 
histology. The relevance of this model relies, firstly, on the localized generation of RPE 
damage that accentuates neuretinal loss due to the merangiotic retina of the rabbit, and 
secondly, on the preclinical imaging methods used for its evaluation. However, a limitation 
could reside on the fact that the described models might not be able to recapitulate progressive 
degeneration due to age. For this purpose, a photooxidative-damage model induced by the 
670 mm-laser light could mimic an aging phenotype in RPE cells that could be worth 
considering as a practically feasible comparison to our models of disease. Also, and despite 
the high costs, the use of non-human primates with a closer retinal physiology with modelled 
GA (chemically-induced with for instance NaIO3 since it is the most suitable for a holangiotic 
retina) would represent the most similar phenotype to the human pathology.  
Thirdly, we show that suspension transplants of hESC-RPE can integrate and form uniform 
monolayers in between PR and choriocapillaries up to eight months if rejection is under 
control, therefore reinforcing that suspension transplants could allow long-term survival of 
functional cells. However, we reported no integration in areas of pronounced GA damage with 
altered RPE/Bruch’s complex. A possible solution will then be the use of sheets or injectable 
hydrogels that could on the one hand facilitate RPE cell integration in a damaged Bruch’s, and 
on the other, assemble the lost retinal elements and nerve connections to resume visual 
function. Although sheets come with the inherent risk of surgical complications and putative 
immune reaction of the transplant, thus requiring further optimization of the implantation 
technology, they might then be a better approach for treatment of late stage GA. However, for 
early stages with a well-preserved subretinal milieu, suspension transplants may be the best 
option. If the cells in suspension manage to integrate in monolayer and mature they (i) could 
suppress the host immune system by the secretion of immunosuppressive factors and the 
expression of certain inhibitory ligand; and (ii) they should be able to cover up to ten times the 
surface of a sheet with a minimally invasive procedure. The use of hydrogels is an option that 
deserves further investigation since some studies have shown their potential in combining the 
  49 
advantages of both sheet and suspensions approaches (Ballios et al., 2015; Ballios et al., 
2010). At this stage, gene therapy may serve to introduce therapeutic genes or factors that 
could also potentiate survival, integration, protection or function of the transplanted cells 
(Gamm et al., 2007). 
Finally, the control of the host immune system is key for the success of the transplantation so 
that the graft does not get rejected acutely in the host tissue. In this respect, the use of iPSC 
should be a safe but expensive way to go. Other strategies include: induction of graft tolerance 
by the host immune system ex vivo, hPSC banking to maximize donor and host HLA matching 
or the production of universal lines of hPSC that would be able to escape the immune system. 
Following this last approach, we generated hESC-RPE lacking HLA-I and upon evaluation of 
their immunological properties they showed to be less immunogenic towards the adaptive 
immune system and presented evidence of a reduced rejection reaction in the xenogeneic 
rabbit model. However, an improved approach would need to be developed at least by (i) 
adding another escaping layer on the adaptive immune system with an HLA-II knock out; (ii) 
avoiding the cytotoxic effect of NK-cells by for instance integrating the HLA-E inhibitory ligand; 
and (iii) the addition of a fail-safe construct that would eliminate the unrecognizable health-
threating engineered cells being infectious or tumorigenic. Additionally, the use of optimized 
humanized models (e.g. mice, rabbit, pig) would be the most plausible way to test with 
reasonable costs and numbers the immunoreactivity of the cells in an allogeneic in vivo 
context.   
To conclude, the overall aim of the therapy suggested in this thesis work is the use of hESC-
RPE cells injected in suspension for the treatment of patients in early stages of GA that could 
serve to slow the progression of the retinal degeneration and preserve as long as possible the 
existent neuretinal layers so that visual functional will not be impaired further. To factually 
restore retinal function and improve vision in late stages of disease, co-transplantation of not 
only RPE but also other neuroretinal cells or progenitors with a biocompatible carrier that 
would facilitate its integration and restoration of the lost neural connections would be required. 
Some years of interdisciplinary research are ahead, aiming to elucidate the specific cues to 
make this last approach a tangible reality for millions of patients suffering from retinal 
blindness.  
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7 POPULAR SCIENCE SUMMARY 
Age-related macular degeneration (AMD) is one of the most common cause of visual loss 
associated with age in the Western countries, accounting for more than eight million people 
affected worldwide. The disease is mainly characterized by the degeneration of one of the 
constituent layers of the retina known as retinal pigment epithelial cells (RPE). RPE carry out 
important functions to maintain the proper functioning of photoreceptor (PR) cells, which are 
in charge of transmitting the visual stimuli to the brain. Therefore, if RPE are damaged, PR 
are in turn also impaired. The advanced form of AMD in which RPE cells die because of 
unknown specific causes has no available treatment today.  
A possible way around it is to replace the lost RPE layer with almost identical cells generated 
in a dish from pluripotent stem cells, i.e. cells with the potentially to become any cell type of 
the body. The establishment of such regenerative approach is actually what this thesis is 
focused on.  
We first developed a methodology to get RPE cells from pluripotent cells derived from human 
embryos in a well-defined manner and with no components of animal origin that could cause 
an immune rejection when transplanted into the human eye. Secondly, we developed an 
animal model (rabbit eye) of disease that recapitulates the main features seen clinically in 
human patients, including both RPE and PR damage. Additionally, this model allowed us to 
use the same surgical and retinal imaging techniques as used in the clinics, therefore 
facilitating the translation of the proposed treatment to the bedside. Thirdly, we demonstrated 
that treating patients in an early stage of the disease with reasonably preserved retinas is 
crucial for the transplanted cells to integrate in the host tissue, and stop the progression of the 
degeneration by preserving the remaining PR. Finally, we developed a strategy for the donor 
cells to escape the immune system by hiding some of the molecules that identify them as 
foreign. We then demonstrated that these modified cells can escape some parts of the 
adaptive immune (T-cells) but not the innate (NK-cells) system, therefore implying that further 
genetic modifications will need to be implemented in the cells to fully avoid their immune 
recognition. When we transplanted the engineered cells into the rabbit eye model, and despite 
the species difference, the early immune reaction of the host was reduced, and the presence 
of anti-human antibodies in the rabbit blood was delayed.  
Altogether these studies show that the treatment of advanced stages of AMD using stem cell 
derived RPE cells can be a tangible possibility if: (i) the derived cells retain properties of the 
native RPE cells; (ii) the cells are transplanted in early stages of the disease with a 
considerably well-conserved retina; and (iii) the cells can be engineered so that they can 
evade the host immune system and consequent graft rejection. Although further investigations 
will need to be carried out to finally bring this therapy in the most efficient, safe and 
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immunocompatible manner, we hope that these studies shed some light on important 
preclinical aspects so that patients suffering from retinal blindness can soon benefit from a 
stem-cell based treatment modality.  
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project, and being involved in it from the very beginning even though you I’m sure you would 
have never imagined to end up in the eye business. JP Shell for sharing some of your lab 
expertise and for all the scientific discussions and fun stories around the lunch table. Nicolás 
Ortega, Nicolasetee, gracias por todas las bromas, las risas y los buenos momentos 
compartidos dentro y fuera del lab! Nerges Winblad, thanks for all the discussions shared 
about CRISPR and about immunology, and for all the good work with the insane WB and clone 
businesses, that both my soul and prayers were all in for those knock outs to (NOT) show up. 
Cheng Zhao, for your always will to help in a patient and nice manner. Sophie Petropoulos, 
love your drive and motivation, thanks for all the inspiring talks about science and Canada 
land, and wish you all the best as a group leader which I have no doubt that will lead to amazing 
science. Sarita Panula, for all the knowledge shared, advice about experiments and 
organizational skills that helped the lab run almost like a charm. You were truly the reference 
PhD student in the lab for all your multiple high-performance skills and I wish you all the best 
in your new GMP challenge! Thanks to former lab members: Theresa Mader, Jie Hao, 
Sebastian Hildebrand, Geeta Ravindran, Philipp Schenk for all the shared moments in the 
lab while I was running around.   
Thanks to Pauliina Damdimopoulou and to her lab members Astrud Tuck, Richelle Duque 
Björnvang for all the fun with celebrations and around the lunch table. And Leni Wagner, for 
all those hand in hand lunchies, fikas, dinners and scientific discussions: from tissue 
stainings/ImageJ, FACS/FJ to single cell RNA sequencing, from eye to ovaries, from CD 
markers to DDX4, from mesenchymal to granulosa cells and from oocytes to RPE cells, at 
any time and place. Thanks for the help you always offered when you saw me in a higher 
speed than usual, and for all the shared moments in and outside the lab that would take me 
another thesis to list up. Still pending in our list is to work side by side under the same project 
(de-frosting the -80°C doesn’t count :P), but some day, in or outside academia we will make it 
happen. Thanks for being how you are. Thanks for your f r i e n d s h i p.  
Thanks to the RPE team, Sara Padrell y Álvaro Plaza por sobrevivir esos periodos intensivos 
de experimentos (sortings, qPCRs, FACSes, validations, teratomas, countingssss, etc) y los 
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never-ending CD/monolayer paper meetings con Fredrik. Gràcies Sara per la teva 
disponibilitat i el bon tarannà que transmets. Gracias Álvaro por las discusiones, por tu 
paciencia y por guiarme en los inicios del RPE project. Esa primera publicación fue un proceso 
intenso pero evidenció que nos entendemos y trabajamos codo con codo de la manera más 
eficiente y precisa. Gracias por tu saber estar, por tu amistad y por todos los momentos vividos 
fuera del lab, que en cuatro años ha habido muchos de memorables :)     
Thanks to the collaborators for your time, your discussions and your knowledge. Without them 
parts of this thesis would not have been easy at all to pursue: Helen Kaipe and Evren Alici, 
for your availability and great discussions about experiments and puzzling results. Laia 
Gorchs per tots els moments compartits a altes hores de la tarda amb els T-cell experiments 
que per una o altra raó acabaven esdevenint hiper-complexes… però sí, sempre ens quedarà 
el sushi! Michael Chrobok and Arnika Wagner thanks for all the scientific discussions, for 
your positive attitude and always will to help out; and Michael for carrying out those never-last-
crazy chromium experiments. Camilla Mohlin for your enthusiasm and help whenever a 
complement question came up. Looking forward to that porcine neuroretinal explants-RPE co-
culture paper!  
Thanks to some KI facilities and their coordinators Iyadh Douagi, Stefan Mienke (FACS 
facility in HERM), Sylvie Le Guyader and Gabriela Imreh (Microscopy facility in BioNut) for 
answering patiently to my panic questions in my early days with your instruments, and for 
sharing all sorts of tips and knowledge to make the best out of them.  
Thanks to CNS and St Eriks officers Mia Pettersson/Susanne Jonson/Maria Persson, Tina 
Melander/Josefine Jarvas, Eva Holmgaard/Kseniya Hartvigsson and Catharina 
Kuylenstierna for always trying to help with some paperwork struggle. Also thanks to you 
Galina Drozdova for being my CLINTEC administrator although me not belonging to it, and 
your help sorting any paperwork/logistic problem efficiently. Thanks for all the other fun 
moments we spent together (also with Alex Lundberg) outside the office-lab space despite 
our packed and uncoordinated lives :) 
Thanks to Tango Restaurang crew for the great spirits, and to its manager Nan-Chung 
Huang for your always positive mood and readiness; and of course, for feeding me many days 
of this PhD! 
During this journey I also engaged in some organizational teams that I truly enjoyed being part 
of (despite the usual moments of craziness on top of the scientific life). Thanks to the all the 
organizing members of the Winter/Ski Conference 2016, 2017, 2018 for the team effort 
resulting in a highly valued and unique conference in KI that allow PhDs to share their scientific 
projects and experiences in a ski setting. Thanks to Magali Merrien, for being my other hand 
pioneering the Huddinge Pubs aiming to entertain the southerner KIs. It was a pleasure to 
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share it with you and was cool to realize how harmonic our party ideas were. Thanks also for 
all the fun times spent together in different formats and around different Stockholm hoods.   
Thanks to all the friends I was lucky to have here in Stockholm, in and outside KI. Thanks for 
each one of the moments of joy we spent together in all sorts of setups: dinners, lunchies, 
brunchies, parties, pubs, concerts, trips, excursions, fikas, BBQs, corridor/flatshares, 
conferences, sports,… during these four years, and that sometimes just popped up last minute 
out of a random text on a Friday or Saturday night :P Without them, any of this scientific 
progress would have happened that smoothly. But let’s keep them up, because I am sure 
there are many more awesome times waiting to come! 
Mauricio Somarribas, el Mauricet, que conozco desde casi el minuto cero en que llegué a 
Estocolmo. Gracias por todos los planes improvisados, por tu música y por tu amistad a lo 
largo del camino. Valentina Carannante, Vale, gracias por tu amistad, por tu tacto y por todas 
las risas y conversaciones compartidas. Aprovecha esta etapa en KI para potenciar tu talento 
científico del que rebosas. Tatiana Álvarez, Tati, l’ànima lliure de KI, m’encanta la teva 
dedicació i capacitat de fer bona feina, keep it up que les dues sabem que d’això en falta. 
Gràcies per tots els moments compartits anytime i malgrat estar fins els topes. Yildiz 
Kelahmetoglu, thanks for all the chipi-squid shared moments especially at the beginning of 
our paths here, that were many. In the end our ways diverged a bit but I know you are there if 
I need. Keep up that drive that makes you move mountains. Jorge Correia, chipi’s other half, 
thanks for your always good mood, sarcastic jokes and scientific motivation that will bring you 
far. Magda Kurek, thanks for being Magda, and for all the time we spent throughout. I’m 
grateful for your hated-back-and-forth trips to Huddinge because they made you come south 
so our friendship could emerge :) And Kuba Lewicki, thanks for all the fun times together, 
and your enthusiasm about SciComm! I’m sure one way or another your scientific creativity 
will shine. And super thanks for accepting being my toastmaster! Rafa González, gracias por 
tu salero, estima y tu buen humor, la diversión está asegurada al salir de cena o copas contigo. 
El viaje a Hawaii nos marcó y siempre nos quedará como un recuerdo único (¡También por el 
infinito trayecto!). Te deseo mucha suerte en esta nueva etapa en tierra sueca :) Burcu 
Bestas, thanks for all our corridor chats while you were listening to horror movies, for all the 
reversed times that now I’m going through, for the guitar moments, and for your open heart 
and friendship. And thanks Cihan Selvi for the good vibes every time I’ve been around you 
both. Vladimir Pabón and Olof Gissberg, for all the corridor times and those unforgettable 
“Beer and Whiskey” festivals. Ksenia Goroshchuk, for those lab-to-lab moments that made 
the everyday frenetic live more enjoyable. Gianvitto Arpino, Gianvittinoooo, thanks for your 
energy and vitality, not having you around the KI events these days is always a bit of a shock 
but your move was for good and I’m happy for you (Sandraaa, Sandraaa!). Alberto Jover, mi 
mañico prefe, muchas gracias por tu autenticidad y por tu cariño. Desde el principio tuvimos 
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una conexión especial. No cambies que vales mucho. Aida Rodríguez, de Asturias a Suecia 
y tiro porque me toca. Gracias por tu buena actitud y por esos momentos guachis de 
MF/Biomedicum pubs o de fiestas caseras. Thanks Lucio Monaco, for being a super fan of 
my choir events and for the fun times around. Gonçalo Brito, the first man I knew even before 
I moved to Stockholm, the CMB pub master, the ski conference promoter, and the Vecura-
Huddinge mate. Thanks for your openness, your charm and for introducing me many of the 
CMB people I know these days. Simona Hankeová, for our moves and laughter, and for our 
lovely retina commons. Pedro Veliça, for the fun pubs, the innebandy games together with 
Deirdre E. Flanagan, and for making science, finally, Pedromics-ally understandable. Wish 
you both the best with the little one that just became part of your lives. David Grommisch and 
Matheus Dyczynski, thanks for all those beers and random chats about live, and David for 
the fun spent together, the scientific talks, THE badminton match and the squash that some 
day will come. Alena Salašová, Alča, thanks for your honesty and for being as you are, and 
for all the cool times spent around together. Susanne Neumann, I’m proud to say that despite 
all the difficulties, we managed a couple of things together that were great fun, but that was 
not enough, we should fix our agendas soon! Thanks for your openness, your positive mood 
and your good spirits that moves crowds. Irene González and Vincent Millischer, thanks for 
the shared dinners around Stockholm. Irene gracias por tu buen hacer, por siempre estar ahí 
y por tu amable hospitalidad. Ana Amaral, thanks for your spontaneity and creative being, 
and thanks for always being opened for any fun or cultural activity that is around :) Agustín 
Solá, gracias por estar siempre dispuesto a poner una mano, por tu buen carácter y por seguir 
animando NEO con los Dead Cell Society pubs. My Årsta girls, Tina Jacob, for all the fun 
times, for your honesty, hard working and awesome leading skills. Was great to work hand in 
hand with you for the last ski conference. Wish you all the best with these exciting times that 
are about to come in your life. And Erle Refsum, my dearest neighbour, for accepting all my 
spontaneous plans, for your charm and easiness. It was always super nice to hang out with 
you. Christine Zimmer, Angelina Schwarz and Magali Merrien, the ethics girl gang, for all 
the awesomely-planned-dinners and enjoyable times together. João P. Alves, thanks for nice 
chats and those very useful thesis tips. Laia Mira, pel teu bon humor i gràcie valenciana que 
portes arreu. Luisa Bone, tú fuiste una de las últimas incorporaciones y me encontraste en 
pre-defence period total. ¡Gracias por todos los momentos improvisados que me sacaban de 
esa locura! Giuseppe Santopolo, Shahul Hameed, Anastasia Magaoulopoulou, Lucía 
Peña, Néstor Aramis, Sharesta Kohenkohen, Silke Sohn, Parisa Rabiei Far, Mihaela 
Zabulica, Renata Vernaitė, Axel Leppert, Médoune Sarr, Ana Marín and Robin Pronk for 
all the fun pub and conference times together. Rosa Sotile, for all the lovely time full of 
laughter we had in Stockholm but also in NYC! Anja Mezger, for our tennis matches and great 
shared moments, wish you all the best now with your new family member. Maria Alsina i 
Jordi Planas, gràcies per tots els moments catalans compartits entre soparets, cantates i 
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BBQs en els meus inicis del doctorat. Clara Márquina y Sera Álvarez, gracias por todas las 
risas compartidas entre impro shows y cenitas. ¡Os deseo lo mejor en Aussie land! Philipp 
Schenk and Julia Karte, you came in the very last bits of this PhD but it truly was a breath of 
fresh air. Thanks for all the shared moments squashing, pizzaing, cake baking, slack-lining… 
it was awesome to have you here, but yess, München is my next obligatory stop! Jess Yi Aile 
Gong, it was a short flatshare but a very enjoyable one. Thanks for those chats and cool 
shared times. Marta Duran and Jon Barreneitxea, my Jägargatan gang, gracias por todas 
las cenas compartidas y por todos los momentos de diversión callejeando por Estocolmo a 
cualquier hora como buenos newbees que fuimos. Clara Kammüller, who would have 
guessed that after our Utrecht time we will both end up in Stockholm and on top living in the 
same building? It was super awesome to have you here and to share those runs, dinners and 
fun events in Swedish land with you. Maria Grazia Cozzupoli, the first girl I met when I 
stepped in St Erik lab four years back, thanks for that first month that was enough to set up a 
very tight mutual bond. Celia Monteagudo, Marta Requena y Sergio Campos, gracias por 
las conversaciones y por todos los buenos momentos compartidos en esos meses de fría 
oscuridad sueca. Luciano di Stefano, Luchiis, por tu sencillez y por esas risas y bailoteos 
entre divas divinas. Nina Kaukua, still missing you in Stockholm, but thanks for the fun shared 
and for all the PhD tips. Pedro Moutinho, Pedriitooooo, for your positive vibe, your craziness 
and your cool way of seeing the world. Tiago Braga, Tiaginhooo, thanks for your always good 
vibes and your participation to any social or musical events that I have been part of. Hara 
Alonso, por tu arte y por nuestras profundas conversaciones de camino a casa después de 
noches intensas en Fylkingen. Lisa Nilsson, my choir soul mate, thanks for your charm and 
for all the shared fun moments in and outside the choir. Johanna Axelsson, Rosario Llenas, 
Violeta de Lama, Ana Andermo, Sara Oppenheimer thanks for the nice times spent 
together in different events and places around Stockholm. Your individual energy is 
uncountable. The Egipcian gang: Karim Elgammal, Mahmoud Ahmed Ismail, Shady 
Mansour, for your always great mood and awesome house parties filled up with cool people 
(and shisha!).  
And from my around periods in Vic, Madrid, Oviedo and The Netherlands: Maria Vila, Laura 
Plancheria, Jenny Caner, Miriam Gutiérrez, Dani Amado per tots els retrobaments UVic 
que reviuen els moments uni i resituen les nostres arrels biotecs. Marta Garrote, pels bons 
moments dins i fora del conservatori, perquè estic segura que la teva perseverància i 
perspicàcia et portarà molt lluny com a metgessa. Jane Kim, Marta Brandt and Sarah 
Gutkind, the girls of the CNIO time, thanks for keeping up the friendship after almost ten years 
of those awesome two months in Madrid. María Suárez, mi Mariniiiiis, ¡Qué haría yo sin 
nuestras dosis! Gracias por todos los momentos compartidos y por ser como eres, porque 
cada vez que nuestros caminos se entrecruzan saltan chispas de la felicidad que rebosamos.  
Anna Oliveras, per la teva autenticitat i per la vocació com a científica que portes a dins. I 
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pels nostres moments asturinanicos entre sidres que sempre ens quedaran en el record. Covi 
Huidobro, por tu hospitalidad, generosidad y buen carácter. Tu constancia y hacer científico 
como doctoranda fue todo un modelo a seguir y que todavía sigo teniendo presente :)   
The Zwolle team: Olga Szczodry, Erica de Zan, David Díaz, Camilla Tomasetta, Niklas 
Stausberg, for all the fun times in and outside Utrecht that were and are about to come, for 
our gang times with “the follow rivers” and for all the craziness that made that year a very 
special one. Sandra Segura, la meva floreta de l’Hubrecht, per tots els bons moments 
utrechtians i per un lligam que perdura de la mà del nostre progrés científic. Miriam Stumpf 
y Virginia Rodríguez, por vuestra amistad y todos los “girl’s moments” en Utrecht, Leiden o 
Amsterdam. Miriam, gracias por tu confianza, y por tu manera de ser comprensible y abierta. 
Vir, gracias por tu genuidad, por las risas, por tu complicidad. Y mil gracias por mandarme 
ese link con una posición de PhD en medicina regenerativa ofrecida por Karolinska que 
marcaría los próximos cuatro años de mi vida. Giulia Meneghello, mi plusitaaaa, gracias por 
tu alegría y vitalidad que te hacen única. Gracias por todos los momentos compartidos entre 
couch surfers en Leiden y por todos los que vinieron después fuera de NL. Ay, ¡La de 
aventuras pendientes que tenemos, plusi! Ilaria My, my first LUMC soul mate, thanks for the 
hand in hand hard work shared in that noisy corridor space, and for all the awesome times we 
spent together out of the lab. Your stay was just for a couple of months but enough to know 
that our friendship will last way longer. Cathelijne van den Berg, Caaat, thanks for all the 
great times in and outside the lab in Leiden. You were my PhD referent when I was still a 
master student and I always valued your hard work and passion. Gracias por todas las 
conversaciones, helados, tapas, paseos en bici... Bedankt voor je echte vriendschap. Klara 
Blom, gracias por tu hospitalidad y por todos los pío-momentos divertidos que pasamos en 
casa. Sofia Gomes, por las risas y tu entusiasmo, ¡Y por las auroras que nos quedan! Pelin 
Gül, for your crazy energy and drive to do things, and for all our guitar moments. Gràcies 
Martina Jutglar, Cèlia Rovira, Marta Mestres and Sandra Juárez, les meves catalanes de 
Leiden i Utrecht per totes les rialles i moments compartits en els que intentàvem arreglar el 
món i més. Gràcies per ser com sou, perquè sou úniques i fantàstiques. Tània Martiáñez y 
Marco Anink, Juan Guadix y Carol Rivas, Román González y Espe Muñoz, gracias por 
todas esas birras y bistecs (Tània!) y por cuidar a la peque del grupo como nadie. Gracias 
Tània, Juan y Román por vuestra inspiración y buen ejemplo científico.  
Thanks to ALL once again for still being part of my life challenging friendship throughout the 
speed of time! 
I com no, els incondicionals de Menorca, de Lô: Moni Pons per sempre ser-hi a pesar d’estar 
enfora i per tots es nostrus “ara o mais”. Vane Gornés per sa teva alegria i es teu cor obert, i 
perquè mai, mai ens llevin es nostrus moments de gavell. Nere Ziarreta y Sara Fernández 
por ser como sóis, por vuestra amistad que no pasa a pesar de los años y porque sé que si 
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necesito estáis ahí y sin falta. Maria Mascaró, per tots es bons compartits des que érem ben 
petites, per es teu bon fer i per s’interès que sempre has tingut sobre el que he anat fent 
recerca. I es Cuxitos meus, per tots es moments compartits cada vegada que sa vigatana, 
sa madrilenya, s’asturiana, s’holandesa o sa sueca d’arrel alaurenca aterrava a sa roqueta. 
Lucas Carreras, Quim Ameller, Sebas Pons, Josep López i Enric Barber, per tots es bons 
moments per Lô per ses festes o per Nadal, i Lucas, per totes ses posades al dia entre cafè i 
cafè en ses que intentam aclarir el món i ses nostres vides científiques. Gràcies Lina Olives, 
per ses xerradetes i per tot es recolzament i ànim que sempre m’has donat. I gràcies Marga 
Pons, per sa teva il·lusió cada vegada que te xerr de sa meva feina i per una amistat que 
creix amb els anys. 
Moltes gràcies de tot cor a sa família Petrus-Reurer, als que hi són i als que ja no hi són, per 
tot es suport i per tota s’estima. Gràcies pares Margaret i Tolo i abuela Catalina per tot el 
que m’hau ensenyat i donat; i per sempre ser-hi, telèfon en mà, passi el que passi i salvant 
qualsevol distància. Gràcies per haver-me inculcat els valors que em fan ser com som, i també 
els de sa feina i de s’esforç que m’han fet arribar fins aquí. Perquè sí, en certa manera sa sort 
se la crea un mateix. Gràcies per haver-me deixat volar tan amunt com ses meves ales han 
volgut. 
 
 
 
 
 “Success is a journey, not a destination”. And indeed, after this particular stretch, I couldn’t 
agree more. But, undoubtedly, the journey continues. 
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